nicotine has been researched along with varenicline in 364 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 81 (22.25) | 29.6817 |
| 2010's | 234 (64.29) | 24.3611 |
| 2020's | 49 (13.46) | 2.80 |
| Authors | Studies |
|---|---|
| Arnold, EP; Bashore, CG; Bianco, KE; Brooks, PR; Coe, JW; Davis, TI; Fox, CB; Lebel, LA; Mansbach, RS; O'Neill, BT; Rollema, H; Sands, SB; Schulz, DW; Tingley, FD; Vetelino, MG; Wirtz, MC | 1 |
| Brieaddy, LE; Burgess, JP; Damaj, MI; Ivy Carroll, F; Lee, JR; Ma, W; Martin, BR; Navarro, HA; Yokota, Y | 1 |
| Carroll, FI; Damaj, MI; Deng, L; Ma, W; Martin, BR; Navarro, HA | 1 |
| Coe, JW; DeNinno, SL; Ellerbrock, B; Gorczyca, R; Horner, W; Hurst, RS; Johnson, DE; Kozak, R; Lowe, JA; MacDougall, MC; Majchrzak, MJ; Mather, RJ; McDowell, LL; Mente, S; Osgood, SM; Rollema, H; Sadlier, J; Shaffer, CL; Shrikhande, A; Tingley, FD; Tritto, T; Ward, KM; Zhang, L | 1 |
| Binda, M; Bolchi, C; Fumagalli, L; Gotti, C; Pallavicini, M; Pistillo, F; Pucci, L; Valoti, E; Vistoli, G | 1 |
| Brunner, D; Caldarone, B; Eaton, JB; Fedolak, A; Hanania, T; Kozikowski, AP; Lukas, RJ; Tückmantel, W; Yu, LF | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Bertrand, D; Bertrand, S; Bréthous, L; Garcia-Delgado, N; Reymond, JL; Schwartz, J | 1 |
| Benson, LR; Bhatti, BS; Breining, SR; Byrd, GD; Fedorov, NB; Hepler, CD; Hooker, DN; Kiser, MN; Lucero, LM; Lukas, RJ; Melvin, M; Mitchener, JP; Reynolds, LA; Sidach, SS; Whiteaker, P; Yohannes, D; Zhang, J | 1 |
| Brunner, D; Eaton, JB; Fedolak, A; Hanania, T; Kozikowski, AP; Lukas, RJ; Yu, LF; Zhang, HK | 1 |
| Al-Muhtasib, N; Brown, ML; Kellar, KJ; Levin, ED; Liu, Y; Paige, M; Rezvani, AH; Richardson, J; Sahibzada, N; Sexton, HG; Tran, T; Xiao, Y; Xie, T; Yenugonda, VM | 1 |
| Al-Muhtasib, N; Brown, ML; Dakshanamurthy, S; Johnson, JE; Kellar, KJ; Kong, HS; Levin, ED; Liu, Y; Paige, M; Rezvani, AH; Sahibzada, N; Slade, S; Tomita, Y; Tran, T; Wells, C; Xiao, Y; Xie, T; Yenugonda, VM | 1 |
| Bartkowiak, JM; Carroll, FI; Castro, AH; Damaj, MI; Luetje, CW; Mascarella, SW; Navarro, HA; Ondachi, PW | 1 |
| Brunner, D; Caldarone, BJ; Eaton, JB; Kozikowski, AP; Lukas, RJ; Onajole, OK; Thiede, L | 1 |
| Carroll, FI; Castro, AH; Damaj, MI; Luetje, CW; Mascarella, SW; Navarro, HA; Ondachi, PW; Ye, Z | 1 |
| Camarelles Guillem, F | 1 |
| Corelli, RL; Hudmon, KS | 1 |
| Burstein, AH; Clark, DJ; Faessel, HM; Gibbs, MA; Rohrbacher, K; Stolar, M | 1 |
| Mogg, A; Peacey, E; Pullar, IA; Smith, JW; Szekeres, P; Tafi, E; Tricklebank, M | 1 |
| Dimoulas, P; Mills, EJ; Wilson, K; Wu, P | 1 |
| Chambers, LK; Coe, JW; Glowa, J; Hurst, RS; Lebel, LA; Lu, Y; Mansbach, RS; Mather, RJ; Rollema, H; Rovetti, CC; Sands, SB; Schaeffer, E; Schulz, DW; Tingley, FD; Williams, KE | 1 |
| Siu, EC; Tyndale, RF | 1 |
| Cahill, K; Lancaster, T; Stead, LF | 5 |
| Frishman, WH | 1 |
| Oberpichler-Schwenk, H | 1 |
| Crane, R | 1 |
| Garwood, CL; Potts, LA | 1 |
| Freedman, R | 1 |
| Croghan, E | 1 |
| Lerman, C; Patterson, F; Schnoll, RA | 1 |
| Doggrell, SA | 1 |
| Hoogendoorn, M; Rutten-van Mölken, MP; Welsing, P | 1 |
| George, TP; Le Foll, B | 1 |
| Milbrandt, A; Ratcliffe, M; Smith, R; Spirling, LI; Stapleton, JA; Sutherland, G; Watson, L | 1 |
| Cohen, AF; Dubois, EA; van Bronswijk, H; Zitman, FG | 1 |
| Andrews, JO; Bennett, SM; Heath, JH | 1 |
| Cahill, K; Lancaster, T; Stead, L | 2 |
| Baker, CL; Bushmakin, AG; Cappelleri, JC; West, R | 1 |
| Cooley, ME; Murphy, M; Sarna, L; Sipples, RL | 1 |
| Aubin, HJ; Billing, CB; Bobak, A; Britton, JR; Gong, J; Oncken, C; Reeves, KR; Williams, KE | 1 |
| Benowitz, NL | 2 |
| Stapleton, JA | 1 |
| Wonnacott, S | 1 |
| Crawford, JT; Goldenberg, RL; Tolosa, JE | 1 |
| Brees, DJ; Cai, JH; Elwell, MR; Finkelstein, MB; Jakowski, AB; Sands, SB; Shen, AC; Tingley, FD | 1 |
| Baker, C; Boler, A; Howard, P; Knight, C | 1 |
| Bölcskei, PL; Walden, K | 1 |
| Tønnesen, P | 2 |
| Bélisle, P; Eisenberg, MJ; Filion, KB; Gervais, A; Joseph, L; Mottillo, S; O'Loughlin, J; Paradis, G; Pilote, L; Rinfret, S; Yavin, D | 1 |
| Rose, JE | 2 |
| Bhowmik, A; Hillman, T; Rajakulasingam, K | 1 |
| Ferguson, SG; Shiffman, S | 1 |
| Reus, VI; Smith, BJ | 1 |
| Filip, M; McCreary, AC; Przegaliński, E; Stefański, R; Zaniewska, M | 1 |
| Carroll, FI; Corrigall, WA; LeSage, MG; Ross, JT; Shelley, D | 1 |
| Bader, P; McDonald, P; Selby, P | 1 |
| Hering, T | 2 |
| Schunack, W | 1 |
| Brace, V; Danielian, P; Rore, C; Williams, D | 1 |
| Ebbert, JO; Hays, JT | 2 |
| Bardo, MT; Crooks, PA; Dwoskin, LP; Joyce, BM; Neugebauer, NM; Pivavarchyk, M; Zhang, Z; Zheng, G | 1 |
| Peiffer, G | 1 |
| Ericson, M; Löf, E; Söderpalm, B; Stomberg, R | 1 |
| McEwen, A; West, R | 1 |
| Aveyard, P; Hajek, P; Inglis, J; Parsons, AC; Shraim, M | 1 |
| Einarson, A; Riordan, S | 1 |
| Florek, E; Piekoszewski, W | 1 |
| Arora, G; Jain, M; Talwar, A | 1 |
| Cornwell, J; Davis, JM; Gupta, S; Lajtha, A; Lindenmayer, JP; Noth, K; Sershen, H; Smith, RC | 1 |
| Ebbert, JO | 1 |
| Burke, MV; Ebbert, JO; Hays, JT; Hurt, RD | 1 |
| Ferguson, SG; Gritz, ER; Henningfield, JE; Shiffman, S | 1 |
| Ashby, CR; Callahan, PM; Gardner, EL; Li, X; Spiller, K; Tehim, A; Xi, ZX | 1 |
| Cryan, JF; Flynn, RA; Glynn, DA; Kennedy, MP; Kent, P | 1 |
| Laniado-Laborín, R | 2 |
| George, TP; Lising-Enriquez, K | 1 |
| Bau, CH; Bizarro, L; Dobler, CJ; Kortmann, GL | 1 |
| Heimlich, L; Steinberg, ML; Williams, JM | 1 |
| Aubin, HJ; Benhaddi, H; Bolin, K; de Nigris, E; Marbaix, S; Mork, AC; Wilson, K | 1 |
| Deissenrieder, F; Groneberg, D; Kusma, B; Mache, S; Quarcoo, D; Welte, T | 1 |
| Keiding, H | 1 |
| Herman, AI; Mooney, M; Sofuoglu, M; Waters, AJ | 1 |
| Maritz, GS | 1 |
| Annemans, L; Bartsch, P; Marbaix, S; Nackaerts, K; Prignot, J | 1 |
| Kranzler, HR; Oncken, CA | 1 |
| Tonstad, S | 1 |
| Davies, C; Gunnell, D; Irvine, D; Martin, RM; Wise, L | 1 |
| Dufour, E; Gardier, AM; Maskos, U; Pons, S; Reperant, C; Rollema, H | 1 |
| Batra, A; Friederich, HM | 1 |
| Mead, AN; O'Connor, EC; Parker, D; Rollema, H | 1 |
| Corelli, RL; Hudmon, KS; Prokhorov, AV | 1 |
| Keating, GM; Lyseng-Williamson, KA | 1 |
| Noda, K; Saku, K; Tsukahara, H | 1 |
| Biala, G; Budzynska, B; Staniak, N | 1 |
| Barr, JD; Bevins, RA; Murray, JE; Reichel, CM | 1 |
| Costa, E; Davis, JM; Guidotti, A; Lajtha, A; Maloku, E; Sershen, H; Smith, RC; Zhubi, A | 1 |
| Ainamo, A; Binnie, VI; Carr, AB; Fundak, A; Koeber, A; Koerber, A; Needleman, IG; Ohrn, K; Rosseel, J | 1 |
| Beck, HN; Biazzo, LL; Campbell, SL; Froshaug, DB; Harwell, TS; Haugland, C; Helgerson, SD | 1 |
| Frey, JM; Jepson, C; Lerman, C; Patterson, F; Phillips, JM; Rudnick, ND; Siegel, SJ; Strasser, AA; Turetsky, BI | 1 |
| Blendy, JA; Castellano, LM; Turner, JR | 2 |
| Biala, G; Staniak, N | 1 |
| Hizue, M; Ishibashi, T; Nomura, S | 1 |
| Bhat, A; Crain, D | 1 |
| Chengappa, KN; Fonte, CA; Jain, A; Lerman, C; Mercincavage, M; Perkins, KA; Stitzer, ML | 1 |
| Ioannides-Demos, LL; McNeil, JJ; Piccenna, L | 1 |
| Lund, KE; McNeill, A; Scheffels, J | 1 |
| Herman, AI; Sofuoglu, M | 1 |
| Ruff, P | 1 |
| Zeller, A | 1 |
| von Garnier, C | 1 |
| Ayesta Ayesta, FJ; Minué Lorenzo, C; Olano Espinosa, E | 1 |
| Carroll, FI; Damaj, MI; George, O; Koob, GF; Lloyd, A | 1 |
| Bover, MT; Foulds, J; Richardson, DL; Schmelzer, AC; Steinberg, MB; Williams, JM | 1 |
| Gnegy, ME; Jutkiewicz, EM; Kim, MN; Zhang, M | 1 |
| Johnson, TS | 1 |
| Cesario, A; Galetta, D; Granone, P; Greenberg, DS; Margaritora, S; Russo, P; Rutella, S; Spaggiari, L; Veronesi, G | 1 |
| Balmford, J; Borland, R; Cummings, KM; Hammond, D | 1 |
| Cunningham, CS; McMahon, LR | 2 |
| Weinsier, ST | 1 |
| Al Rubaiy, SA; Bloom, SA; Guendisch, D; Papke, RL; Trocmé-Thibierge, C | 1 |
| Ebbert, J; Erwin, PJ; Montori, VM; Stead, LF | 1 |
| De Vries, TJ; De Vries, W; Pattij, T; Riga, D; Schetters, D; Schoffelmeer, AN; Stegeman, M; van Mourik, Y; Wouda, JA | 1 |
| Grief, SN | 1 |
| Dong, E; Guidotti, A; Kadriu, B; Maloku, E; Pibiri, F; Satta, R; Zhubi, A | 1 |
| Díaz Cerezo, S; Martí Sánchez, B; Navarro Artieda, R; Sanz De Burgoa, V; Sicras Mainar, A | 1 |
| Bartlett, SE; Bito-Onon, JJ; Chatterjee, S; Holgate, J; Simms, JA | 1 |
| Coleman, T; Huang, Y; Langley, TE; Lewis, S; McNeill, A; Szatkowski, L | 1 |
| Gur, RC; Lerman, C; Loughead, J; O'Donnell, GP; Ray, R; Ruparel, K; Senecal, N; Siegel, S; Wileyto, EP | 1 |
| Simon, JA | 1 |
| Aubin, HJ; Karila, L; Reynaud, M | 1 |
| Bircher, R; Chen, W; DiFranza, JR; Heffernan, M; Huang, W; King, J; Rane, P; Shields, J | 1 |
| Agboola, S; Coleman, T; Leonardi-Bee, J; McNeill, A; Taylor, M | 1 |
| Coleman, T; Lewis, S; McNeill, A; Szatkowski, L | 1 |
| Foulds, J; Gandhi, KK; Steinberg, MB; Steinberg, ML; Ulpe, R; Williams, JM | 1 |
| Belcon, AL | 1 |
| Marti, J | 1 |
| Brooks, EA; Jutkiewicz, EM; Kynaston, AD; Rice, KC; Woods, JH | 1 |
| Czoty, PW; Gould, RW; Nader, MA; Nader, SH | 1 |
| Kadokura, Y; Kano, M; Kushihashi, Y; Saito, H; Shino, M; Suzaki, H; Suzuki, M; Takiguchi, S; Yamada, Y | 1 |
| Barnes, C; Chakraborty-Chatterjee, M; Gamaleddin, I; Goldberg, SR; Khaled, M; Le Foll, B; Lev-Ran, S; Pushparaj, A; Yan, Y | 1 |
| Baker, TB; Fiore, MC | 1 |
| Caggiula, AR; Donny, EC; Levin, ME; Palmatier, MI; Sved, AF; Weaver, MT | 1 |
| Ansermot, N; Choong, E; Cornuz, J; Dobrinas, M; Eap, CB; Noetzli, M | 1 |
| Furberg, CD; Glenmullen, J; Maltsberger, JT; Moore, TJ; Singh, S | 1 |
| Grady, SR; Marks, MJ; O'Neill, HC; Ortiz, NC | 1 |
| Ammerman, S; Bailey, SR; Crew, EE; Killen, JD; Riske, EC; Robinson, TN | 1 |
| Schuurmans, MM; Zellweger, JP | 1 |
| Azar, MR; Cohen, A; Fox, BS; George, O; Goeders, NE; Koob, GF | 1 |
| Cunningham, CS; Javors, MA; McMahon, LR | 1 |
| Etter, JF; Schneider, NG | 1 |
| Bordia, T; Chin, M; Hrachova, M; McIntosh, JM; Quik, M | 1 |
| Gallagher, T; Haseler, CA; Rucktooa, P; Sixma, TK; Smit, AB; van Elk, R | 1 |
| Papke, RL; Stokes, C | 1 |
| Browning, KK; Diaz, P; Ferketich, AK; Koletar, SL; Lu, B; Reynolds, NR; Wewers, ME | 1 |
| Ashare, RL; Blair, IA; Leone, F; Mesaros, AC; Strasser, AA; Tang, KZ | 1 |
| Akk, G; Esch, C; Herder, P; Laughlin, JR; Li, P; Stitzel, JA; Tammimäki, A | 1 |
| Blendy, JA; Cousins, V; Hussmann, GP; Kellar, KJ; Levin, ED; Lomazzo, E; Perry, DC; Rezvani, AH; Turner, JR; Venkatesh, R; Wolfe, BB; Xiao, Y; Yasuda, RP | 1 |
| Garg, PK; Garg, S; Gould, RW; Nader, MA | 1 |
| Holloway, AC; Nicholson, CJ; Raha, S; Woynillowicz, AK | 1 |
| Mikkelsen, K; Tønnesen, P | 1 |
| Anthony, JC; Behm, FM; Eaton, WW; Fisher, C; Ialongo, N; Musci, R; Rose, JE; Storr, CL; Uhl, GR; Walther, D | 1 |
| Almgren, MM; Clark, KJ; Stroman, RT; Wynn, WP | 1 |
| Biała, G; Budzyńska, B; Kruk-Słomka, M | 1 |
| Baker, TB; Benowitz, NL; Bergen, AW; Conti, DV; Edlund, CK; Hall, S; Javitz, HS; Krasnow, R; Kwok, PY; Lee, W; Lerman, C; Liu, J; Michel, M; Nishita, D; Swan, GE; Tyndale, RF | 1 |
| Dixon-McDougall, T; Nowak, C; Pereira, S; Qian, C; Sellings, L; Tyndale, RF; van der Kooy, D; Zhao, B | 1 |
| Damborsky, JC; DuBois, DW; Fincher, AS; Frye, GD; Winzer-Serhan, UH | 1 |
| Milnerowicz, H; Sliwińska-Mossoń, M; Zieleń, I | 1 |
| Porwal, M; Tsoi, DT; Webster, AC | 1 |
| Carroll, AJ; Hong, LE; Ross, TJ; Salmeron, BJ; Stein, EA; Sutherland, MT | 1 |
| Brown, VL; Cinciripini, PM; Engelmann, JM; Karam-Hage, M; Lam, C; Minnix, JA; Robinson, JD; Versace, F; Wetter, DW | 1 |
| Blendy, JA; Carlson, GC; Gould, TJ; Poole, RL; Turner, JR; Wilkinson, DS | 1 |
| Berg, A; Foulds, J; Franzon, M; Galaznik, A; Hughes, JR; Russ, C; Yu, CR; Zou, KH | 1 |
| Antilla, JC; Bickford, PC; Engberg, ME; Hudson, CE; Kang, CW; Lambert, CS; Philpot, RM; Rowell, PP; Wecker, L; Zesiewicz, TA | 1 |
| Fagerström, KO; Jiménez-Ruiz, CA | 1 |
| Brasic, JR; Chamroonrat, W; Dannals, RF; Gao, Y; Gean, EG; Horti, AG; Kim, J; Kuwabara, H; Mathur, A; McCaul, ME; Valentine, H; Wand, G; Willis, W; Wong, DF | 1 |
| Brown, J; Kotz, D; West, R | 2 |
| Hajek, P; Hartmann-Boyce, J; Jarvis, M; Lancaster, T; Stead, LF; West, R | 1 |
| Alexander, JC; Bruijnzeel, AW; Igari, M; Ji, Y; Papke, RL; Qi, X | 1 |
| Kaakkola, S; Tuominen, R | 1 |
| Dow, WH; Rungruanghiranya, S; White, JS | 1 |
| Checa-Andrés, MD; Esparza-Martín, N; García-Cantón, C; Guerra-Rodríguez, R; Ramírez-Puga, A; Suria-González, S | 1 |
| Goutier, W; Kloeze, MB; McCreary, AC | 1 |
| Carroll, FI; Fivel, PA; Kohut, SJ; Mello, NK | 1 |
| Eapen, S; Mills, EJ; Prochaska, JJ; Thorlund, K; Wu, P | 1 |
| Bertrand, D; Hurst, RS; Lee, TC; Rollema, H; Russ, C | 1 |
| Blendy, JA; DeDominicis, KE; Forcelli, PA; Hussmann, GP; Kellar, KJ; Klehm, J; Lindstrom, J; Richardson, JR; Sahibzada, N; Turner, JR; Wolfe, BB; Xiao, Y; Yasuda, RP | 1 |
| Gupta, T; Jain, R; Majumder, P | 1 |
| Cieślewicz, A; Jabłecka, A; Korzeniowska, K | 1 |
| Daughton, DM; Rennard, SI | 1 |
| Buyukuysal, S; Coskun, AS; Goktalay, G; Goktalay, T; Kayir, H; Uslu, G; Uzbay, T; Yorgancioglu, A | 1 |
| Ebbert, JO; Elrashidi, MY | 1 |
| Argue, DP; Cousin, MA; Ebbert, JO; Ekker, SC; Klee, EW; Urban, MD; Wiinamaki, AR | 1 |
| Møller, AM; Thomsen, T; Villebro, N | 1 |
| Andrea, D; Braida, D; Cannazza, G; Clementi, F; Fasoli, F; Gotti, C; Manfredi, I; Papke, RL; Ponzoni, L; Pucci, L; Sala, M; Stokes, C | 1 |
| Arteaga, C; Brosky, G; Oh, P; Ranger, S; Raymond, V; Selby, P | 1 |
| Abdool-Gaffar, MS; Bateman, ED; Bruning, A; Emanuel, S; Esterhuizen, TM; Irusen, EM; Koegelenberg, CF; Noor, F; O'Brien, JA; Smith, C; van Zyl-Smit, RN | 1 |
| Kuryatov, A; Ley, CK; Lindstrom, JM; Wang, J | 1 |
| Faessel, HM; Gastonguay, MR; Lee, TC; Niaura, R; Ravva, P | 1 |
| Caggiula, AR; Donny, EC; Levin, ME; Palmatier, MI; Schassburger, RL; Sved, AF; Weaver, MT | 1 |
| Fisher, DC; Fletcher, PJ; Guy, EG; Higgins, GA | 1 |
| Baena, A; Masuet-Aumatell, C; Morchon, S; Ramon, JM | 1 |
| Steurer, J | 1 |
| Abe, S; Imaizumi, S; Kawachi, E; Matsuo, Y; Miura, S; Noda, K; Saku, K; Shimizu, T; Suematsu, Y; Takata, K; Tsukahara, H; Uehara, Y; Yahiro, E; Zhang, B | 1 |
| Hogarth, L; Panlilio, LV; Shoaib, M | 1 |
| Ciccocioppo, R; Cippitelli, A; Gaiolini, KA; Gorman, M; Khroyan, TV; Mercatelli, D; Pascual, C; Ramirez, A; Schoch, J; Toll, L; Wu, J; Xie, XS; Yasuda, D; Zaveri, NT | 1 |
| Davies, NM; Munafò, MR; Ware, JJ | 1 |
| Benowitz, NL; Cinciripini, P; George, TP; Hawk, LW; Heitjan, DF; Lerman, C; Schnoll, RA; Swan, GE; Tyndale, RF; Wileyto, EP | 1 |
| Hall, BJ; Levin, ED; Rose, JE; Slade, S; Wells, C | 1 |
| Bergman, J; Desai, RI | 1 |
| Fedota, JR; Hong, LE; Ross, TJ; Salmeron, BJ; Stein, EA; Sutherland, MT | 1 |
| Baker, NL; Carpenter, MJ; Gray, KM; Hartwell, KJ; McClure, EA; Ramakrishnan, V; Saladin, ME | 1 |
| Borland, R; Brady, K; Carpenter, MJ; Cummings, KM; Fong, GT; Hartwell, K; Hyland, A; Kasza, KA; McKee, SA; Smith, PH | 1 |
| Chang, Q; Hanania, T; Maillet, EL; Mash, DC | 1 |
| Chenoweth, MJ; Cinciripini, PM; George, TP; Hawk, LW; Lerman, C; Novalen, M; Schnoll, RA; Tyndale, RF | 1 |
| Butt, CM; Grady, SR; Marks, MJ; McIntosh, JM; O'Neill, HC; Ortiz, NC; Short, CA; Simmons, EE; Wynalda-Camozzi, KM | 1 |
| Tashkin, DP | 1 |
| He, Y; Sun, S; Wu, L; Zeng, J | 1 |
| Benowitz, NL; Prochaska, JJ | 1 |
| Bevins, RA; Dwoskin, LP; Pittenger, ST; Zeplin, LC | 1 |
| Coen, K; Funk, D; Lê, AD; Lo, S | 1 |
| Ciccocioppo, R; Cippitelli, A; Scuppa, G; Toll, L; Ubaldi, M | 1 |
| Ebbert, JO; Elrashidi, MY; Stead, LF | 1 |
| Clemens, KJ; Holmes, NM; Lay, BP | 1 |
| Abdullah, R; Banks, ML; Bettinger, JC; Carroll, FI; Damaj, IM; Dawson, A; Jackson, A; Miles, MF; Muldoon, PP; O'Brien, M; Slater, CA; Soll, LG; Tapper, AR | 1 |
| Abe, TO; Gaya, PV; Pereira, AC; Pinheiro, GG; Santos, PC; Scholz, J; Silva, AP | 1 |
| Seguí Díaz, M | 1 |
| Baker, TB; Bolt, DM; Fiore, MC; Fraser, DL; Piper, ME; Smith, SS; Stein, JH | 1 |
| Wise, J | 1 |
| Banks, ML; Blough, BE; Smith, DA | 1 |
| Clemens, KJ; Holmes, NM; Macnamara, CL; Westbrook, RF | 1 |
| Prochaska, JJ | 1 |
| Carroll, ME; Smethells, JR; Swalve, N | 1 |
| Cahill, K; Fanshawe, TR; Lancaster, T; Lindson-Hawley, N; Thomas, KH | 1 |
| Abe, TO; Amorim, C; Buzo, CG; Gaya, PV; Lopes, NH; Pereira, AC; Pierri, H; Santos, PC; Scholz, J | 1 |
| Della Santa, P | 1 |
| Blazekovic, S; Brubaker, TR; Hitsman, B; Hole, A; Kalhan, R; Langer, C; Leone, F; Patel, J; Price, S; Schnoll, R; Veluz-Wilkins, A; Wileyto, EP | 1 |
| Ban, N; Hamajima, N; Hasegawa, Y; Murohara, T; Oguri, T; Okada, Y; Sato, M; Shimadu, S | 1 |
| Besheer, J; Cannady, R; Randall, PA | 1 |
| Buhidma, Y; Jackson, A; Shoaib, M; Silk, S | 1 |
| Kotz, D; van der Meer, RM; van Eerd, EA; van Schayck, OC | 1 |
| Emme, E; Mazure, CM; McKee, SA; Smith, PH; Weinberger, AH; Zhang, J | 1 |
| Carroll, FI; Cunningham, CS; Javors, MA; McMahon, LR; Moerke, MJ | 1 |
| Albillos, A; Blázquez, J; de Castro-Guerín, C; González-Enguita, C; Hone, AJ; Michael McIntosh, J; Passas, J; Rueda-Ruzafa, L | 1 |
| Gass, JC; Germeroth, LJ; Hawk, LW; Moore, FE; Motschman, CA; Munoz, DA; Rhodes, JD; Schlienz, NJ; Tiffany, ST; Wray, JM | 1 |
| Muheim, L | 1 |
| de Moura, FB; McMahon, LR | 2 |
| Izumi, T; Ohmura, Y; Sasamori, H; Tsutsui-Kimura, I; Yoshida, T; Yoshioka, M | 1 |
| Clyde, M; Els, C; Pipe, A; Reid, R; Tulloch, H | 1 |
| Chappell, K; Ferguson, SG; Jacobson, GA; Lu, W; Patel, R; Schüz, N; Walters, JAE | 1 |
| Aronson, SE; Lesage, E; Ross, TJ; Salmeron, BJ; Stein, EA; Sutherland, MT | 1 |
| Batsikadze, G; Grundey, J; Hasan, A; Kuo, MF; Nitsche, MA; Paulus, W | 1 |
| Colby, SM; MacKillop, J; Martin, RA; Murphy, CM; Rohsenow, DJ; Tidey, JW | 1 |
| Baraona, LK; Daniels, JL; Lovelace, D; McDaniel, L | 1 |
| Acuña Izcaray, A; Alfageme Michavila, I; Buljubasich, D; Casas, A; Chatkin, JM; de Granda Orive, JI; Guerreros Benavides, A; Jiménez Ruiz, CA; Noé, V; Núñez-Sánchez, I; Paez Espinel, N; Palomar Lever, A; Riesco Miranda, JA; Sánchez-Angarita, E; Sansores, RH; Zabert, G | 1 |
| Govind, AP; Green, WN; Stolz, JR; Swanson, GT; Vallejo, YF; Yan, JZ | 1 |
| Benowitz, NL; Cinciripini, P; George, TP; Hawk, LW; Lerman, C; Morales, M; Nollen, NL; Peng, AR; Schnoll, R; Tyndale, RF; Wileyto, EP | 1 |
| Davies, NM; Jones, T; Martin, RM; Munafò, MR; Taylor, AE; Taylor, GMJ; Thomas, KH; Windmeijer, F | 1 |
| Cornuz, J; Csajka, C; Dobrinas, M; Eap, CB; Gholamrezaee, M; Glatard, A; Lubomirov, R | 1 |
| Abney, L; Beaulieu, DB; Duncan, MS; Freiberg, MS; Gatskie, V; Greevy, RA; King, S; Kundu, S; Scoville, E; Tindle, HA; Tyndale, RF; Wells, QS | 1 |
| Bagdas, D; Hamouda, AK; Imad Damaj, M; Jackson, A | 1 |
| Ginsburg, BC; Lamb, RJ; Levy, SA | 1 |
| Bardo, MT; Baxter, TA; Bell, RL; Crooks, P; Dwoskin, LP; Maggio, SE; Newman, AH; Nixon, K; Prendergast, MA; Saunders, MA; Slack, RD; Zheng, G | 1 |
| Barrett, ST; Bevins, RA; Geary, TN; Steiner, AN | 1 |
| Abdul-Kader, J; Airagnes, G; D'almeida, S; Le Faou, AL; Limosin, F | 1 |
| Bambs S, C; Cerda L, J; Corvalán B, MP; Pavié G, J; Véjar M, L; Zagolin B, M | 1 |
| Harika-Germaneau, G; Jaafari, N; Peiffer, G; Perriot, J; Underner, M | 1 |
| Clark, A; Clyde, M; Els, C; Fu, A; Pipe, A; Reid, R; Tulloch, H | 1 |
| Alkhlaif, Y; Bagdas, D; Carroll, FI; Damaj, MI; Ditre, JW; Jackson, A | 1 |
| Clemens, KJ; Davis, A; Holmes, NM; Pan, J; Panayi, MC | 1 |
| Fukumoto, K; Kusaba, M; Mizoguchi, H; Wang, T; Yamada, K | 1 |
| Cinciripini, P; George, TP; Hawk, LW; Lerman, C; Peng, AR; Schnoll, R; Tyndale, RF | 1 |
| Aksöyler, DY; Aksu, AE; Bitik, O; Çalış, M; Kösemehmetoğlu, K; Üstün, GG; Uzun, H | 1 |
| Aveyard, P; Coleman, T; Hajek, P; Lewis, S; Lindson, N; Munafo, M | 1 |
| Adams, R; Ahmed, K; Alekna, R; Anderson, EC; Anderson, R; Ataya-Williams, A; Attwood, A; Aveyard, P; Banting, M; Bisal, N; Coleman, T; Coyle, D; Coyle, K; Dickinson, A; Easey, K; Fluharty, M; Freuler, T; Hajek, P; Healy, M; Homsey, C; Hurse, M; Khan, S; Khouja, J; Lacey, L; Lewis, S; Li, J; Lindson, N; Lycett, D; McEwen, A; McRobbie, HJ; Munafò, M; Myers-Smith, K; Orton, S; Perdue, J; Phillips, A; Pokhrel, S; Przulj, D; Rai, G; Randall, C; Tearne, S; Wood, C | 1 |
| McMahon, LR; Moerke, MJ | 1 |
| Bedi, G; Comer, SD; Cooper, ZD; Foltin, RW; Haney, M; Herrmann, ES; Ramesh, D; Reed, SC | 1 |
| Bardo, MT; Bell, RL; Crooks, PA; Dwoskin, LP; Maggio, SE; Nixon, K; Prendergast, MA; Saunders, MA; Zheng, G | 1 |
| Absalom, NL; Ahring, PK; Balle, T; Chebib, M; Indurthi, DC; Lewis, TM; Liao, VW; Qudah, T | 1 |
| Charntikov, S; Kazan, T | 1 |
| McMahon, LR | 1 |
| Leischow, SJ | 1 |
| Carroll, AJ; Hitsman, B; Hole, A; Jao, NC; Kalhan, R; Langer, C; Leone, F; Lubitz, SF; Miele, A; Patel, J; Paul Wileyto, E; Schnoll, R; Veluz-Wilkins, A | 1 |
| Bao, H; Bera, K; Bishara, I; Borden, PM; Chapman, ER; Cohen, B; Dougherty, DA; Jeon, J; Kim, C; Lester, HA; Looger, LL; Marvin, JS; Mulcahy, MJ; Muthusamy, AK; Nichols, AL; O'Riordan, SL; Shivange, AV | 1 |
| Hajek, P; Hartmann-Boyce, J; Jarvis, M; Livingstone-Banks, J; Norris, E; West, R | 1 |
| Hauser, SR; Knight, CP; McBride, WJ; Pratt, LA; Rodd, ZA; Waeiss, RA | 1 |
| de Abreu, GR; de Souza Spinosa, H; Faria Waziry, PA; Flório, JC; Fukushima, AR; Lebrun, I; Moreira, N; Petrocelli, BM; Reis-Silva, TM; Ricci, EL; Sandini, TM; Zaccarelli-Magalhães, J | 1 |
| Barrett, ST; Bevins, RA; Thompson, BM | 1 |
| Brath, H; Fasching, P; Kaser, S; Tatschl, C | 1 |
| Baker, TB; Cook, JW; Piper, ME; Schlam, TR; Smith, SS | 1 |
| Dannals, RF; Kuwabara, H; McCaul, ME; Wand, GS; Wong, D; Xu, X | 1 |
| Brousse, G; de Chazeron, I; Harika-Germaneau, G; Jaafari, N; Peiffer, G; Perriot, J; Schmitt, A; Underner, M | 1 |
| Alayoubi, H; Alkhlaif, Y; AlOmari, D; Bagdas, D; Carper, M; Damaj, MI; Diester, CM; Poklis, JL; Riley, J | 1 |
| Cornuz, J; Jacot Sadowski, I; Rat, C; Selby, K | 1 |
| Le Foll, B; Trigo, JM | 1 |
| Davies, NM; Itani, T; Jones, T; Martin, RM; Munafò, MR; Rai, D; Taylor, AE; Taylor, GMJ; Thomas, KH; Windmeijer, F | 1 |
| Eberg, M; Filion, KB; Platt, RW; Reynier, P | 1 |
| Barkat, SS; Eloma, AS; Tellier, SM | 1 |
| Flannery, JS; Laird, AR; Poudel, R; Riedel, MC; Ross, TJ; Salmeron, BJ; Stein, EA; Sutherland, MT | 1 |
| Inada, K; Kanaoka, Y; Kataoka, Y; Koga, M; Nakao, Y; Okamoto, M; Takayama, S; Yamauchi, A | 1 |
| Davis, CM; Holtyn, AF; Weerts, EM | 1 |
| Davies, NM; Itani, T; Jones, T; Martin, RM; Munafò, MR; Rai, D; Taylor, AE; Taylor, GMJ; Thomas, KH | 1 |
| Havard, A; Kennedy, D; Lee, ML; Tran, DT; Welsh, A | 1 |
| Lesage, E; Ross, TJ; Salmeron, BJ; Stein, EA; Sutherland, MT | 1 |
| Charntikov, S; Cova, N; Kazan, T; Madore, VM; Robison, CL | 1 |
| Abney, LR; Adams, DW; Beaulieu, DB; Freiberg, MS; Gatskie, V; Gurwara, S; Horst, SN; King, S; Peyton, SC; Pointer, SO; Schwartz, DA; Scoville, EA; Tindle, HA; Wells, QS | 1 |
| Bardo, MT; Chandler, CM; Maggio, SE; Nixon, K; Peng, H | 1 |
| Amos, CI; Baker, TB; Bierut, LJ; Bray, M; Carney, RM; Chen, J; Chen, LS; Culverhouse, RC; Jorenby, DE; Miller, JP; Saccone, NL; Smock, N; Stoneking, F | 1 |
| Firth, J; Kisely, S; Siskind, DJ; Wong, TT; Wu, BT | 1 |
| Ashare, RL; Bauer, AM; Flitter, A; Gross, R; Hitsman, B; Hosie Quinn, M; Leone, FT; Lubitz, SF; Schnoll, R | 1 |
| Barrett, ST; Charntikov, S; Hart, E; Hertia, D | 1 |
| Barrett, ST; Bevins, RA; Huynh, YW; Kwan, DA; Murray, JE; Thompson, BM | 1 |
| Ding, ZM; Gao, Y; Sentir, AM; Tan, X | 1 |
| Antoniu, SA; Buculei, I; Crisan Dabija, R; Mihaltan, F; Trofor, AC | 1 |
| Higgins, GA; Sellers, EM | 1 |
| Achenbach, C; Ashare, R; Bauer, AM; Fox, EN; Gollan, J; Gross, R; Hatzell, J; Hitsman, B; Josephson, S; Leone, F; Purnell, J; Quinn, MH; Randle, T; Rogers, T; Schnoll, R; Stevens, N; Wileyto, EP | 1 |
| Albillos, A; Blázquez, J; de Los Ríos, C; González-Enguita, C; Hone, AJ; Jiménez-Pompa, A; Medina-Polo, J; Michael McIntosh, J; Rueda-Ruzafa, L; Sanz-Lázaro, S | 1 |
| de Chazeron, I; Jaafari, N; Peiffer, G; Perriot, J; Ruppert, AM; Underner, M | 1 |
| Choi, SKY; Einarsdottir, K; Havard, A; Jorm, LR; Kemp-Casey, A; Preen, DB; Randall, D; Tran, DT | 1 |
| Chenoweth, MJ; Hawk, LW; Novalen, M; Tyndale, RF; Zhao, B | 1 |
| Evers-Casey, S; Leone, FT | 1 |
| Beloate, LN; Doolittle, J; Froeliger, B; Garcia-Keller, C; Kalivas, PW; Meyerink, ME; Nall, RW; Penaloza, T | 1 |
| Chakraborti, Y; Coffman, DL; Piper, ME | 1 |
| George, TP; Johnstone, S; Rabin, RA; Sorkhou, M | 1 |
| Abramson, MJ; Bonevski, B; George, J; Gobarani, RK; Ilomäki, J; Wood, S | 1 |
| Humair, JP; Papachristou, C | 1 |
| Apolone, G; Boeri, M; Boffi, R; Gallus, S; Ladisa, V; Ledda, RE; Marchianò, A; Milanese, G; Munarini, E; Pastorino, U; Rolli, L; Sabia, F; Sozzi, G; Suatoni, P; Trussardo, S; Valsecchi, C | 1 |
| Bendiks, S; Blokhina, E; Bryant, K; Cheng, DM; Freiberg, MS; Gnatienko, N; Hahn, J; Krupitsky, E; Lioznov, D; Patts, G; Samet, JH; So-Armah, K; Stein, MD; Tindle, HA; Yaroslavtseva, T | 1 |
| Bhuiyan, M; Chen, CT; Freifelder, R; Govind, AP; Green, WN; Holderman, N; Kao, CM; Kucharski, A; Mitchell, S; Mukherjee, J; Zammit, M; Zhang, HJ; Zhuang, X | 1 |
| Baliunas, D; Comans, T; Gartner, C; Hollingworth, SA; Pole, JD; Sullivan, C | 1 |
| Barrett, ST; Bevins, RA; Dwoskin, LP; Huynh, YW; Thompson, BM; Tracy, ME | 1 |
| Chenoweth, MJ; Knight, J; Lerman, C; Tyndale, RF | 1 |
| Chow, CK; Falster, MO; Filion, KB; Havard, A; Hsu, B; Jorm, L; Pearson, SA; Robijn, AL; Woodward, M | 1 |
| Buzzi, B; Damaj, MI; Koseli, E; Moncayo, L; Shoaib, M | 1 |
| Burkard, T; Christ-Crain, M; Coynel, D; Erlanger, TE; Hemkens, LG; Jeanloz, N; Lengsfeld, S; Meienberg, A; Speich, B; Vogt, DR; Winzeler, B; Zanchi, D | 1 |
| Canseco, JA; D'Antonio, ND; Heard, JC; Karamian, BA; Kepler, CK; Lambrechts, MJ; Levy, HA; Markova, DZ; Vaccaro, AR; Yalla, GR | 1 |
| Fanshawe, TR; Hajizadeh, A; Hartman, L; Lindson, N; Livingstone-Banks, J; Theodoulou, A; Thomas, KH | 1 |
| Ashburner, JM; Klemenc Ketiš, Z; Oreskovic, S; Oreskovic, T; Percac-Lima, S; Rifel, J; Tiljak, H | 1 |
| Ahluwalia, JS; Cox, LS; Ellerbeck, EF; Greiner, KA; Leavens, ELS; Mayo, MS; Nollen, NL; Salzman, G; Shanks, D; Woodward, J | 1 |
| Budzyńska, B; Chałas, R; Maciąg, M; Rahnama-Hezavah, M; Stachurski, P; Świątkowska, A; Świątkowski, W; Tylżanowski, P | 1 |
| Dennis, BB; Devereaux, PJ; Fairbairn, N; Lu, C; Mbuagbaw, L; Ofori, S; Olasupo, OO | 1 |
| Davis, JM; Masclans, L; Rose, JE | 1 |
| Agrawal, S; Aveyard, P; Fanshawe, TR; Freeman, SC; Hajizadeh, A; Hartmann-Boyce, J; Lindson, N; Livingstone-Banks, J; Ordóñez-Mena, JM; Sutton, AJ; Theodoulou, A; Zhu, S | 1 |
| Barnes, J; Bullen, C; Calder, A; Laking, G; Parag, V; Walker, N | 1 |
| Ahluwalia, JS; Brown, A; Cruvinel, E; Funk, O; Lambart, L; Leavens, E; Mayo, MS; Nollen, NL; Sanderson Cox, L | 1 |
99 review(s) available for nicotine and varenicline
| Article | Year |
|---|---|
Pharmacologic interventions for smoking cessation.
Topics: Administration, Cutaneous; Administration, Inhalation; Antidepressive Agents, Second-Generation; Benzazepines; Bupropion; Chewing Gum; Clonidine; Critical Care; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Nicotine; Nicotinic Agonists; Nortriptyline; Nurse's Role; Patient Education as Topic; Patient Selection; Phytotherapy; Piperidines; Pyrazoles; Quinoxalines; Rimonabant; Smoking Cessation; Smoking Prevention; United States; United States Food and Drug Administration; Varenicline | 2006 |
Effectiveness of smoking cessation therapies: a systematic review and meta-analysis.
Topics: Benzazepines; Bupropion; Humans; Nicotine; Quinoxalines; Smoking Cessation; Treatment Outcome; Varenicline | 2006 |
Non-nicotinic therapies for smoking cessation.
Topics: Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Drugs, Investigational; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2007 |
Nicotine receptor partial agonists for smoking cessation.
Topics: Alkaloids; Azocines; Benzazepines; Humans; Nicotine; Nicotinic Agonists; Quinolizines; Quinoxalines; Randomized Controlled Trials as Topic; Smoking Cessation; Varenicline | 2007 |
Smoking cessation pharmacotherapy--nicotine and non-nicotine preparations.
Topics: Administration, Cutaneous; Administration, Inhalation; Benzazepines; Bupropion; Chewing Gum; Clonidine; Coronary Artery Disease; Humans; Monoamine Oxidase Inhibitors; Nicotine; Nortriptyline; Piperidines; Pyrazoles; Quinoxalines; Receptors, Nicotinic; Rimonabant; Selective Serotonin Reuptake Inhibitors; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder; Tobacco, Smokeless; Varenicline | 2007 |
The most addictive drug, the most deadly substance: smoking cessation tactics for the busy clinician.
Topics: Age Factors; Benzazepines; Bupropion; Complementary Therapies; Dopamine Uptake Inhibitors; Dosage Forms; Humans; Nicotine; Nicotinic Agonists; Physician's Role; Primary Health Care; Quinoxalines; Referral and Consultation; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2007 |
Varenicline: the newest agent for smoking cessation.
Topics: Animals; Benzazepines; Clinical Trials, Phase III as Topic; Drug Interactions; Humans; Nicotine; Quinoxalines; Receptors, Cholinergic; Smoking Cessation; Varenicline | 2007 |
Optimizing on smoke free legislation making the most of the opportunity.
Topics: Benzazepines; Bupropion; Decision Trees; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Health Services Needs and Demand; Humans; Nicotine; Nicotinic Agonists; Nurse's Role; Patient Care Planning; Patient Education as Topic; Practice Guidelines as Topic; Public Facilities; Quinoxalines; Smoking; Smoking Cessation; Smoking Prevention; Social Support; United Kingdom; Varenicline | 2007 |
Treating tobacco dependence in women.
Topics: Benzazepines; Bupropion; Counseling; Dopamine Uptake Inhibitors; Female; Humans; Lung Neoplasms; Nicotine; Nicotinic Agonists; Quinoxalines; Risk Reduction Behavior; Smoking; Smoking Cessation; Smoking Prevention; Tobacco Use Disorder; United States; Varenicline; Women's Health | 2007 |
Which is the best primary medication for long-term smoking cessation--nicotine replacement therapy, bupropion or varenicline?
Topics: Benzazepines; Bupropion; Combined Modality Therapy; Counseling; Dopamine Uptake Inhibitors; Drug Administration Routes; Drug Partial Agonism; Drug Therapy, Combination; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Time Factors; Treatment Outcome; Varenicline | 2007 |
Treatment of tobacco dependence: integrating recent progress into practice.
Topics: Behavior Therapy; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Health Behavior; Health Policy; Humans; Nicotine; Nicotinic Agonists; Practice Guidelines as Topic; Quinoxalines; Tobacco Use Cessation; Tobacco Use Disorder; Varenicline | 2007 |
Breaking the ties of nicotine dependence.
Topics: Algorithms; Benzazepines; Bupropion; Decision Trees; Dopamine Uptake Inhibitors; Drug Costs; Evidence-Based Medicine; Global Health; Humans; Nicotine; Nicotinic Agonists; Nurse Practitioners; Nurse's Role; Nursing Assessment; Patient Acceptance of Health Care; Patient Care Planning; Patient Education as Topic; Practice Guidelines as Topic; Prevalence; Primary Health Care; Quinoxalines; Risk Factors; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2007 |
An update on therapeutics for tobacco dependence.
Topics: Alkaloids; Anti-Anxiety Agents; Azocines; Benzazepines; Bupropion; Clinical Trials as Topic; Databases, Bibliographic; Humans; Nicotine; Nicotinic Agonists; Piperidines; Pyrazoles; Quinolizines; Quinoxalines; Review Literature as Topic; Rimonabant; Smoking; Smoking Cessation; Varenicline | 2008 |
Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt.
Topics: Adolescent; Adult; Affect; Aged; Benzazepines; Bupropion; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Dopamine Uptake Inhibitors; Double-Blind Method; Follow-Up Studies; Humans; Middle Aged; Motivation; Multicenter Studies as Topic; Nicotine; Nicotinic Agonists; Quinoxalines; Randomized Controlled Trials as Topic; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder; Varenicline | 2008 |
Smoking cessation and lung cancer: oncology nurses can make a difference.
Topics: Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Humans; Information Services; Lung Neoplasms; Nicotine; Oncology Nursing; Quinoxalines; Smoking; Smoking Cessation; Varenicline | 2008 |
Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction.
Topics: Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Asian; Benzazepines; Black or African American; Bupropion; Cotinine; Cues; Cytochrome P-450 CYP2A6; Drug Tolerance; Genetic Predisposition to Disease; Harm Reduction; Humans; Menthol; Mixed Function Oxygenases; Neuronal Plasticity; Nicotine; Nicotinic Agonists; Quinoxalines; Receptors, Nicotinic; Reinforcement, Psychology; Smoking; Smoking Cessation; Tobacco Use Disorder; United States; Varenicline; White People | 2008 |
Smoking cessation in pregnancy: why, how, and what next...
Topics: Behavior Therapy; Benzazepines; Bupropion; Counseling; Female; Humans; Nicotine; Pregnancy; Pregnancy Outcome; Quinoxalines; Smoking; Smoking Cessation; Smoking Prevention; Varenicline | 2008 |
[The ABC of smoking cessation].
Topics: Antidepressive Agents, Second-Generation; Benzazepines; Bupropion; Cognitive Behavioral Therapy; Humans; Hypnosis; Motivation; Nicotiana; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Varenicline | 2008 |
Which drug to be used in smoking cessation?
Topics: Benzazepines; Bupropion; Humans; Nicotine; Quinoxalines; Smoking Cessation; Treatment Outcome; Varenicline | 2008 |
Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials.
Topics: Administration, Cutaneous; Administration, Inhalation; Administration, Oral; Benzazepines; Bupropion; Chewing Gum; Female; Follow-Up Studies; Humans; Male; Multivariate Analysis; Nicotine; Nicotinic Agonists; Patient Compliance; Probability; Quebec; Quinoxalines; Risk Assessment; Smoking; Smoking Cessation; Smoking Prevention; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2008 |
Nicotine receptor partial agonists for smoking cessation.
Topics: Alkaloids; Azocines; Benzazepines; Bupropion; Humans; Nicotine; Nicotinic Agonists; Quinolizines; Quinoxalines; Randomized Controlled Trials as Topic; Smoking; Smoking Cessation; Varenicline | 2008 |
The relevance and treatment of cue-induced cravings in tobacco dependence.
Topics: Adaptation, Psychological; Antidepressive Agents, Second-Generation; Benzazepines; Bupropion; Cognitive Behavioral Therapy; Cues; Extinction, Psychological; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2009 |
Drugs for tobacco dependence.
Topics: Adrenergic alpha-Agonists; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2008 |
Multimodal techniques for smoking cessation: a review of their efficacy and utilisation and clinical practice guidelines.
Topics: Benzazepines; Combined Modality Therapy; Complementary Therapies; Drug Therapy, Combination; Humans; Nicotine; Nicotinic Agonists; Practice Guidelines as Topic; Psychotherapy; Quinoxalines; Smoking Cessation; Smoking Prevention; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2008 |
Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics.
Topics: Animals; Behavior, Addictive; Benzazepines; Bupropion; Ganglionic Stimulants; Humans; Nicotine; Nicotinic Agonists; Nonprescription Drugs; Quinoxalines; Smoking; Tobacco Use Disorder; Varenicline | 2009 |
[Modern medical support for smoking cessation].
Topics: Benzazepines; Bupropion; Humans; Nicotine; Practice Patterns, Physicians'; Quinoxalines; Smoking Cessation; Smoking Prevention; Varenicline | 2009 |
[Not smoking, essential for healthy lungs].
Topics: Administration, Cutaneous; Benzazepines; Bupropion; Chewing Gum; Health; Humans; Lung; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Tablets; Varenicline | 2008 |
Smoking cessation in pregnancy.
Topics: Animals; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Female; Humans; Nicotine; Nicotinic Agonists; Pregnancy; Pregnancy Complications; Quinoxalines; Smoking Cessation; Varenicline | 2008 |
Varenicline for tobacco dependence.
Topics: Benzazepines; Brain; Coronary Artery Disease; Humans; Male; Middle Aged; Motivation; Nicotine; Nicotinic Agonists; Practice Guidelines as Topic; Pulmonary Disease, Chronic Obstructive; Quinoxalines; Receptors, Nicotinic; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2008 |
New findings on nicotine addiction and treatment.
Topics: Animals; Benzazepines; Bupropion; Humans; Mecamylamine; Motivation; Nicotine; Nicotinic Antagonists; Quinoxalines; Reward; Smoking Cessation; Tobacco Use Disorder; Vaccines; Varenicline | 2009 |
Interventions for preventing weight gain after smoking cessation.
Topics: Antidepressive Agents; Benzazepines; Exercise; Female; Humans; Male; Nicotine; Nicotinic Agonists; Piperidines; Pyrazoles; Quinoxalines; Rimonabant; Smoking Cessation; Varenicline; Weight Gain | 2009 |
Smoking in pregnancy and lactation: a review of risks and cessation strategies.
Topics: Adult; Alkaloids; Antidepressive Agents; Azocines; Benzazepines; Breast Feeding; Bromocriptine; Cognitive Behavioral Therapy; Female; Humans; Lactation; Nicotine; Nicotinic Agonists; Pregnancy; Pregnancy Complications; Quinolizines; Quinoxalines; Risk Assessment; Risk Factors; Smoking; Smoking Cessation; Vaccines; Varenicline; Young Adult | 2009 |
[Pharmacotherapy of smoking cessation with application of nicotine and nicotine free drugs].
Topics: Benzazepines; Bupropion; Humans; Nicotine; Quinoxalines; Receptors, Nicotinic; Smoking; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2008 |
A preliminary benefit-risk assessment of varenicline in smoking cessation.
Topics: Antidepressive Agents, Second-Generation; Benzazepines; Bupropion; Humans; Nicotine; Nicotinic Agonists; Product Surveillance, Postmarketing; Quinoxalines; Recurrence; Risk Assessment; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Varenicline | 2009 |
Emerging drugs for the treatment of tobacco dependence.
Topics: Animals; Benzazepines; Clinical Trials as Topic; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Receptors, Nicotinic; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2009 |
Tobacco dependence and withdrawal: science base, challenges and opportunities for pharmacotherapy.
Topics: Animals; Benzazepines; Bupropion; Clinical Trials as Topic; Humans; Nicotine; Quinoxalines; Receptors, Nicotinic; Substance Withdrawal Syndrome; Tobacco Use Cessation; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2009 |
Update on smoking cessation therapies.
Topics: Antidepressive Agents, Second-Generation; Benzazepines; Bupropion; Cost of Illness; Drug Approval; Global Health; Humans; Morbidity; Nicotine; Nicotinic Agonists; Quinoxalines; Safety; Smoking; Smoking Cessation; Smoking Prevention; Treatment Outcome; United States; Varenicline | 2009 |
Smoking and chronic obstructive pulmonary disease (COPD). Parallel epidemics of the 21 century.
Topics: Benzazepines; Bupropion; Combined Modality Therapy; Dopamine Uptake Inhibitors; Humans; Nicotine; Nicotinic Agonists; Pulmonary Disease, Chronic Obstructive; Quinoxalines; Smoking; Smoking Cessation; Varenicline | 2009 |
Pharmacogenetics of smoking cessation therapy.
Topics: Benzazepines; Bupropion; Clonidine; Genome-Wide Association Study; Humans; Nicotine; Nortriptyline; Pharmacogenetics; Quinoxalines; Smoking Cessation; Varenicline | 2010 |
Tobacco use among individuals with intellectual or developmental disabilities: a brief review.
Topics: Adult; Benzazepines; Bupropion; Counseling; Cross-Sectional Studies; Disabled Persons; Health Policy; Humans; Nicotine; Persons with Mental Disabilities; Quinoxalines; Smoking; Smoking Cessation; Tobacco Smoke Pollution; Tobacco Use Disorder; United States; Varenicline | 2009 |
Are nicotine replacement therapy, varenicline or bupropion options for pregnant mothers to quit smoking? Effects on the respiratory system of the offspring.
Topics: Animals; Antioxidants; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Female; Humans; Maternal-Fetal Exchange; Nicotine; Nicotinic Agonists; Pregnancy; Pregnancy Complications; Quinoxalines; Respiratory System; Smoking; Smoking Cessation; Smoking Prevention; Tobacco Use Disorder; Varenicline | 2009 |
What do we know about the role of pharmacotherapy for smoking cessation before or during pregnancy?
Topics: Animals; Benzazepines; Bupropion; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Nicotine; Pregnancy; Quinoxalines; Randomized Controlled Trials as Topic; Smoking; Smoking Cessation; Varenicline | 2009 |
Current approaches to pharmacotherapy for smoking cessation.
Topics: Adolescent; Adult; Animals; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Female; Humans; Male; Nicotine; Nicotinic Agonists; Pregnancy; Quinoxalines; Smoking Cessation; Smoking Prevention; Tobacco Use Disorder; United States; Varenicline | 2010 |
Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation.
Topics: Benzazepines; Bupropion; Clinical Trials as Topic; Cost-Benefit Analysis; Delayed-Action Preparations; Health Care Costs; Humans; Models, Statistical; Nicotine; Nicotinic Agonists; Prevalence; Quinoxalines; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2010 |
Smoking cessation intervention: an evidence-based approach.
Topics: Antidepressive Agents, Second-Generation; Behavior Therapy; Benzazepines; Bupropion; Directive Counseling; Drug Therapy, Combination; Evidence-Based Medicine; Global Health; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Smoking Prevention; Varenicline | 2010 |
Improving the effectiveness of tobacco use cessation (TUC).
Topics: Antidepressive Agents, Second-Generation; Behavior Therapy; Benzazepines; Bupropion; Chewing Gum; Counseling; Dental Offices; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Referral and Consultation; Smoking; Tobacco Use Cessation; Varenicline | 2010 |
[Pharmacological profile and clinical findings on varenicline tartrate (Champix tablets)].
Topics: Animals; Benzazepines; Clinical Trials, Phase III as Topic; Corpus Striatum; Dopamine; Humans; Nicotine; Nicotinic Agonists; Nucleus Accumbens; Quinoxalines; Receptors, Nicotinic; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2010 |
Smoking cessation-recent advances.
Topics: Australia; Benzazepines; Bupropion; Cardiovascular Diseases; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Humans; Immunotherapy, Active; Nicotine; Nicotinic Agonists; Quinoxalines; Randomized Controlled Trials as Topic; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Transdermal Patch; Treatment Outcome; United Kingdom; United States; Varenicline | 2010 |
Comparison of available treatments for tobacco addiction.
Topics: Behavior Therapy; Benzazepines; Bupropion; Humans; Nicotine; Nortriptyline; Quinoxalines; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2010 |
[Preventive relapse treatment for tobacco cessation - is it worthwhile?].
Topics: Antidepressive Agents; Behavior Therapy; Benzazepines; Bupropion; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Randomized Controlled Trials as Topic; Secondary Prevention; Smoking Cessation; Treatment Outcome; Varenicline | 2010 |
[Pharmacotherapies for nicotine dependence: review of scientific evidence. Spanish Society of Smoking Specialists: recommendations about election and individualization].
Topics: Benzazepines; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Tobacco Use Disorder; Varenicline | 2011 |
A brief review of pharmacotherapeutic treatment options in smoking cessation: bupropion versus varenicline.
Topics: Antidepressive Agents, Second-Generation; Behavior Therapy; Benzazepines; Bupropion; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Risk Factors; Smoking Cessation; Smoking Prevention; Substance-Related Disorders; Varenicline | 2010 |
Impact of genetic variability in nicotinic acetylcholine receptors on nicotine addiction and smoking cessation treatment.
Topics: Benzazepines; Bupropion; Genetic Variation; Humans; Nicotine; Protein Subunits; Quinoxalines; Receptors, Nicotinic; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2011 |
Adverse effects and tolerability of medications for the treatment of tobacco use and dependence.
Topics: Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2010 |
Nicotine receptor partial agonists for smoking cessation.
Topics: Alkaloids; Azocines; Benzazepines; Bupropion; Humans; Nicotine; Nicotinic Agonists; Quinolizines; Quinoxalines; Randomized Controlled Trials as Topic; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Varenicline | 2010 |
Interventions for smokeless tobacco use cessation.
Topics: Benzazepines; Bupropion; Chewing Gum; Counseling; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Randomized Controlled Trials as Topic; Tobacco Use Cessation; Tobacco, Smokeless; Varenicline | 2011 |
Nicotine receptor partial agonists for smoking cessation.
Topics: Alkaloids; Azocines; Benzazepines; Bupropion; Humans; Nicotine; Nicotinic Agonists; Quinolizines; Quinoxalines; Randomized Controlled Trials as Topic; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Varenicline | 2011 |
Nicotine dependence: health consequences, smoking cessation therapies, and pharmacotherapy.
Topics: Administration, Cutaneous; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Heart Diseases; Humans; Neoplasms; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Smoking Prevention; Substance-Related Disorders; Varenicline | 2011 |
Pharmacotherapy for smoking cessation: present and future.
Topics: Adolescent; Animals; Benzazepines; Bupropion; Delayed-Action Preparations; Female; Humans; Nicotine; Nicotinic Agonists; Pregnancy; Quinoxalines; Smoking Cessation; Smoking Prevention; Tobacco Use Disorder; Varenicline | 2011 |
Varenicline for tobacco dependence: panacea or plight?
Topics: Animals; Benzazepines; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Tobacco Use Cessation; Tobacco Use Disorder; Tobacco, Smokeless; Varenicline | 2011 |
Clinical practice. Treating smokers in the health care setting.
Topics: Benzazepines; Bupropion; Cholinergic Agents; Counseling; Dopamine Uptake Inhibitors; Evidence-Based Medicine; Female; Humans; Middle Aged; Motivation; Nicotine; Patient Compliance; Physician-Patient Relations; Practice Guidelines as Topic; Quinoxalines; Smoking; Smoking Cessation; United States; Varenicline | 2011 |
Efficacy and tolerability of pharmacotherapies to aid smoking cessation in adolescents.
Topics: Adolescent; Benzazepines; Bupropion; Clinical Trials as Topic; Dopamine Uptake Inhibitors; Humans; Nicotine; Nicotinic Agonists; Patient Compliance; Prescription Drugs; Quinoxalines; Randomized Controlled Trials as Topic; Safety; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Cessation Devices; Treatment Outcome; Varenicline | 2012 |
[Smoking cessation in medical practice--new possibilities?].
Topics: Benzazepines; Bupropion; Complementary Therapies; Drugs, Investigational; General Practitioners; Humans; Nicotine; Nicotinic Agonists; Professional Practice; Quinoxalines; Smoking; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline | 2012 |
Nicotine receptor partial agonists for smoking cessation.
Topics: Alkaloids; Azepines; Azocines; Benzazepines; Bupropion; Counseling; Heterocyclic Compounds, 4 or More Rings; Humans; Nicotine; Nicotinic Agonists; Quinolizines; Quinoxalines; Randomized Controlled Trials as Topic; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Varenicline | 2012 |
The pharmacist "toolbox" for smoking cessation: a review of methods, medicines, and novel means to help patients along the path of smoking reduction to smoking cessation.
Topics: Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Education, Pharmacy, Continuing; Humans; Nicotine; Nicotinic Agonists; Patient Acceptance of Health Care; Pharmacists; Quinoxalines; Smoking; Smoking Cessation; Smoking Prevention; Tobacco Use Cessation Devices; Varenicline | 2012 |
[Drugs used to treat nicotine addiction].
Topics: Adult; Age Distribution; Alkaloids; Azocines; Benzazepines; Bupropion; Causality; Comorbidity; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Poland; Quinolizines; Quinoxalines; Sex Distribution; Smoking; Smoking Cessation; Smoking Prevention; Tobacco Use Disorder; Varenicline; Young Adult | 2012 |
Interventions for smoking cessation and reduction in individuals with schizophrenia.
Topics: Adult; Antidepressive Agents, Second-Generation; Benzazepines; Bupropion; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Randomized Controlled Trials as Topic; Reinforcement, Psychology; Schizophrenia; Schizophrenic Psychology; Smoking Cessation; Smoking Prevention; Tobacco Use Cessation Devices; Varenicline | 2013 |
Smoking cessation and COPD.
Topics: Benzazepines; Bupropion; Counseling; Humans; Nicotine; Nicotinic Agonists; Prevalence; Pulmonary Disease, Chronic Obstructive; Quinoxalines; Risk Factors; Risk Reduction Behavior; Smoking; Smoking Cessation; Smoking Prevention; Tobacco Use Cessation Devices; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2013 |
Smoking cessation treatment for COPD smokers: the role of pharmacological interventions.
Topics: Benzazepines; Bupropion; Humans; Nicotine; Pulmonary Disease, Chronic Obstructive; Quinoxalines; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline | 2013 |
Relapse prevention interventions for smoking cessation.
Topics: Behavior Therapy; Benzazepines; Chewing Gum; Female; Humans; Male; Nicotine; Nicotinic Agonists; Pregnancy; Quinoxalines; Randomized Controlled Trials as Topic; Secondary Prevention; Smoking Cessation; Smoking Prevention; Varenicline | 2013 |
[Nicotine and neurologic diseases--even a noxious substance may possess beneficial properties].
Topics: Alzheimer Disease; Ataxia; Benzazepines; Cognitive Dysfunction; Epilepsy, Frontal Lobe; Humans; Mutation; Nicotine; Nicotinic Agonists; Parkinson Disease; Quinoxalines; Receptors, Nicotinic; Tobacco Use Cessation Devices; Varenicline | 2013 |
Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis.
Topics: Adult; Benzazepines; Bupropion; Cardiovascular Diseases; Dopamine Uptake Inhibitors; Female; Humans; Male; Nicotine; Nicotinic Agonists; Quinoxalines; Risk Factors; Smoking; Smoking Cessation; Varenicline | 2014 |
Pharmacological intervention of nicotine dependence.
Topics: Benzazepines; Bupropion; Humans; Nicotine; Quinoxalines; Tobacco Use Cessation Devices; Tobacco Use Disorder; Varenicline | 2013 |
Smoking cessation.
Topics: Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Humans; Nicotine; Nicotinic Agonists; Pulmonary Disease, Chronic Obstructive; Quinoxalines; Smoking; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline | 2014 |
Emerging drugs for the treatment of tobacco dependence: 2014 update.
Topics: Atomoxetine Hydrochloride; Benzazepines; Bupropion; Clinical Trials as Topic; Clonidine; Humans; Mecamylamine; Nicotine; Nortriptyline; Propylamines; Quinoxalines; Tobacco Use Cessation Devices; Tobacco Use Disorder; Varenicline | 2014 |
Interventions for preoperative smoking cessation.
Topics: Benzazepines; Humans; Nicotine; Nicotinic Agonists; Postoperative Complications; Preoperative Care; Quinoxalines; Randomized Controlled Trials as Topic; Smoking; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline | 2014 |
Smoking Cessation in Chronic Obstructive Pulmonary Disease.
Topics: Combined Modality Therapy; Counseling; Electronic Nicotine Delivery Systems; Humans; Nicotine; Nicotinic Agonists; Pulmonary Disease, Chronic Obstructive; Secondary Prevention; Smoking; Smoking Cessation; Treatment Outcome; Varenicline | 2015 |
Effect of Smoking Reduction Therapy on Smoking Cessation for Smokers without an Intention to Quit: An Updated Systematic Review and Meta-Analysis of Randomized Controlled.
Topics: Adult; Aged; Benzazepines; Bupropion; Female; Humans; Intention; Male; Middle Aged; Nicotine; Nicotinic Agonists; Quinoxalines; Randomized Controlled Trials as Topic; Smoking; Smoking Cessation; Varenicline | 2015 |
The Past, Present, and Future of Nicotine Addiction Therapy.
Topics: Alkaloids; Azocines; Bupropion; Directive Counseling; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Health Policy; Humans; Nicotine; Nicotinic Agonists; Quinolizines; Smoking Cessation; Social Media; Text Messaging; Tobacco Use Cessation Devices; Tobacco Use Disorder; Varenicline | 2016 |
Interventions for smokeless tobacco use cessation.
Topics: Benzazepines; Bupropion; Chewing Gum; Counseling; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Randomized Controlled Trials as Topic; Tobacco Use Cessation; Tobacco, Smokeless; Varenicline | 2015 |
Nicotine receptor partial agonists for smoking cessation.
Topics: Alkaloids; Azepines; Azocines; Benzazepines; Bupropion; Counseling; Heterocyclic Compounds, 4 or More Rings; Humans; Nicotine; Nicotinic Agonists; Quinolizines; Randomized Controlled Trials as Topic; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Varenicline | 2016 |
Smoking cessation for people with chronic obstructive pulmonary disease.
Topics: Adult; Behavior Therapy; Bupropion; Combined Modality Therapy; Female; Humans; Male; Nicotine; Nicotinic Agonists; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Smoking Cessation; Varenicline | 2016 |
Sex Differences in Smoking Cessation Pharmacotherapy Comparative Efficacy: A Network Meta-analysis.
Topics: Adult; Female; Humans; Male; Nicotine; Nicotinic Agonists; Sex Distribution; Smoking; Smoking Cessation; Tobacco Use Cessation Devices; Treatment Outcome; Varenicline | 2017 |
Selection criteria limit generalizability of smoking pharmacotherapy studies differentially across clinical trials and laboratory studies: A systematic review on varenicline.
Topics: Adult; Bupropion; Clinical Trials as Topic; Female; Humans; Laboratories; Middle Aged; Nicotine; Nicotinic Agonists; Patient Selection; Smoking; Smoking Cessation; Varenicline | 2016 |
Tobacco Harms, Nicotine Pharmacology, and Pharmacologic Tobacco Cessation Interventions for Women.
Topics: Bupropion; Female; Fetus; Humans; Lactation; Nicotiana; Nicotine; Pregnancy; Pregnant Women; Smoking; Smoking Cessation; Tobacco Use Cessation; Tobacco Use Cessation Devices; Tobacco Use Disorder; Varenicline | 2017 |
[Interventions for smoking cessation in 2018].
Topics: Bupropion; History, 21st Century; Humans; Nicotine; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline | 2018 |
[Smoking cessation: Pharmacological strategies different from standard treatments].
Topics: Bupropion; Humans; Nicotine; Smoking; Smoking Cessation; Smoking Cessation Agents; Standard of Care; Tobacco Use Cessation Devices; Varenicline | 2018 |
Green tobacco sickness: mecamylamine, varenicline, and nicotine vaccine as clinical research tools and potential therapeutics.
Topics: Agricultural Workers' Diseases; Humans; Mecamylamine; Nicotiana; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Plant Leaves; Vaccines; Varenicline | 2019 |
Relapse prevention interventions for smoking cessation.
Topics: Behavior Therapy; Bupropion; Chewing Gum; Female; Humans; Male; Nicotine; Nicotinic Agonists; Pregnancy; Randomized Controlled Trials as Topic; Secondary Prevention; Smoking Cessation; Smoking Cessation Agents; Smoking Prevention; Varenicline | 2019 |
[Smoking, alcohol and diabetes (Update 2019)].
Topics: Alcohol Drinking; Benzazepines; Bupropion; Diabetes Mellitus; Humans; Nicotine; Practice Guidelines as Topic; Quinoxalines; Smoking; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline | 2019 |
[Stopping and reducing smoking in patients with schizophrenia].
Topics: Bupropion; Cognitive Behavioral Therapy; Electronic Nicotine Delivery Systems; Humans; Nicotine; Reinforcement, Psychology; Schizophrenia; Smoking Cessation; Tobacco Smoking; Tobacco Use Cessation Devices; Varenicline | 2019 |
[Smoking cessation: How can we involve patients better in treatment choice?]
Topics: Bupropion; Choice Behavior; Counseling; Decision Making, Shared; Humans; Nicotine; Patient Participation; Patient Selection; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline | 2019 |
Pharmacological interventions for smoking cessation among people with schizophrenia spectrum disorders: a systematic review, meta-analysis, and network meta-analysis.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Humans; Network Meta-Analysis; Nicotine; Nicotinic Agonists; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Smoking Cessation; Varenicline | 2020 |
Pharmacological strategies for smoking cessation in patients with chronic obstructive pulmonary disease: a pragmatic review.
Topics: Benzazepines; Bupropion; Humans; Nicotine; Pulmonary Disease, Chronic Obstructive; Quinoxalines; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline | 2021 |
[Combinations of pharmacological treatments in smoking cessation. A systematic review].
Topics: Bupropion; Humans; Nicotine; Smoking; Smoking Cessation; Varenicline | 2021 |
Tobacco Use Disorder.
Topics: Behavior, Addictive; Bupropion; Combined Modality Therapy; Counseling; Drug Therapy; Electronic Nicotine Delivery Systems; Humans; Morbidity; Neurobiology; Nicotine; Nicotinic Agonists; Phenotype; Prevalence; Smoking Cessation; Smoking Cessation Agents; Tobacco Use Cessation Devices; Tobacco Use Disorder; United States; Varenicline | 2022 |
Nicotine receptor partial agonists for smoking cessation.
Topics: Alkaloids; Bupropion; Electronic Nicotine Delivery Systems; Humans; Nicotine; Nicotinic Agonists; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline | 2023 |
Cytisine for smoking cessation: A systematic review and meta-analysis.
Topics: Adult; Alkaloids; Azocines; Benzazepines; Bupropion; Humans; Nicotine; Nicotinic Agonists; Quinolizines; Smoking Cessation; Varenicline | 2023 |
Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses.
Topics: Adult; Bupropion; Electronic Nicotine Delivery Systems; Female; Humans; Network Meta-Analysis; Nicotine; Nortriptyline; Pregnancy; Smoking Cessation; Varenicline | 2023 |
52 trial(s) available for nicotine and varenicline
| Article | Year |
|---|---|
Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers.
Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Benzazepines; Cotinine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Half-Life; Headache; Humans; Hypotension, Orthostatic; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Nicotine; Patient Dropouts; Quinoxalines; Receptors, Nicotinic; Smoking; Smoking Cessation; Smoking Prevention; Tablets; Varenicline; Vomiting | 2006 |
Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Benzazepines; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Patient Compliance; Quinoxalines; Reinforcement, Psychology; Smoking Cessation; Smoking Prevention; Substance Withdrawal Syndrome; Treatment Outcome; Varenicline | 2008 |
Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzazepines; Carbon Dioxide; Cognition; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Neuropsychological Tests; Nicotine; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Quinoxalines; Schizophrenia; Schizophrenic Psychology; Smoking; Time Factors; Varenicline | 2009 |
Varenicline attenuates some of the subjective and physiological effects of intravenous nicotine in humans.
Topics: Adult; Affect; Benzazepines; Blood Pressure; Cognition Disorders; Cotinine; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Rate; Humans; Injections, Intravenous; Male; Middle Aged; Neuropsychological Tests; Nicotine; Nicotinic Agonists; Quinoxalines; Severity of Illness Index; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2009 |
A randomized controlled open comparative trial of varenicline vs nicotine patch in adult smokers: efficacy, safety and withdrawal symptoms (the VN-SEESAW study).
Topics: Administration, Cutaneous; Adult; Benzazepines; Emotions; Endpoint Determination; Female; Humans; Incidence; Male; Middle Aged; Nicotine; Nicotinic Agonists; Quinoxalines; Risk Factors; Smoking; Smoking Cessation; Stress, Psychological; Substance Withdrawal Syndrome; Treatment Outcome; Varenicline | 2010 |
Mouse model predicts effects of smoking and varenicline on event-related potentials in humans.
Topics: Adult; Animals; Benzazepines; Cross-Over Studies; Evoked Potentials; Female; Humans; Male; Mice; Mice, Inbred C57BL; Nicotine; Placebo Effect; Quinoxalines; Smoking; Varenicline; Young Adult | 2010 |
Cross-validation of a new procedure for early screening of smoking cessation medications in humans.
Topics: Administration, Cutaneous; Adult; Benzazepines; Cross-Over Studies; Data Interpretation, Statistical; Double-Blind Method; Drug Evaluation, Preclinical; Female; Humans; Male; Motivation; Nicotine; Nicotinic Agonists; Quinoxalines; Reproducibility of Results; Research Design; Smoking; Smoking Cessation; Surveys and Questionnaires; Varenicline | 2010 |
Brain activity and emotional processing in smokers treated with varenicline.
Topics: Adolescent; Adult; Affect; Aged; Amygdala; Analysis of Variance; Benzazepines; Brain; Cross-Over Studies; Double-Blind Method; Emotions; Facial Expression; Female; Functional Neuroimaging; Humans; Linear Models; Magnetic Resonance Imaging; Male; Middle Aged; Nicotine; Nicotinic Agonists; Oxygen; Photic Stimulation; Placebos; Quinoxalines; Reaction Time; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Treatment Outcome; Varenicline; Young Adult | 2013 |
Safety of varenicline among smokers enrolled in the lung HIV study.
Topics: Adult; Benzazepines; Female; HIV Infections; Humans; Male; Middle Aged; Nicotine; Prospective Studies; Quinoxalines; Smoking Cessation; Treatment Outcome; Varenicline | 2013 |
Effects of 21 days of varenicline versus placebo on smoking behaviors and urges among non-treatment seeking smokers.
Topics: Adult; alpha7 Nicotinic Acetylcholine Receptor; Behavior, Addictive; Benzazepines; Biomarkers; Cotinine; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Nausea; Nicotine; Nicotinic Agonists; Patient Acceptance of Health Care; Pennsylvania; Quinoxalines; Receptors, Nicotinic; Smoking Cessation; Substance Withdrawal Syndrome; Time Factors; Varenicline; Young Adult | 2012 |
Varenicline to stop long-term nicotine replacement use: a double-blind, randomized, placebo-controlled trial.
Topics: Benzazepines; Body Weight; Double-Blind Method; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Antagonists; Placebos; Quinoxalines; Smoking Cessation; Substance Withdrawal Syndrome; Surveys and Questionnaires; Varenicline | 2013 |
Smoking quit success genotype score predicts quit success and distinct patterns of developmental involvement with common addictive substances.
Topics: Adolescent; Benzazepines; Bupropion; Case-Control Studies; Cohort Studies; Dose-Response Relationship, Drug; Female; Genotype; Humans; Male; Nicotine; Outcome Assessment, Health Care; Polymorphism, Single Nucleotide; Quinoxalines; Reproducibility of Results; Risk Factors; Smoking Cessation; Substance-Related Disorders; Tobacco Use Cessation Devices; Tobacco Use Disorder; Varenicline; Young Adult | 2014 |
Nicotinic acetylcholine receptor variation and response to smoking cessation therapies.
Topics: Adult; Antidepressive Agents, Second-Generation; Behavior Therapy; Benzazepines; Bupropion; Female; Genotype; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Polymorphism, Single Nucleotide; Quinoxalines; Receptors, Nicotinic; Recurrence; Smoking; Smoking Cessation; Varenicline | 2013 |
Down-regulation of amygdala and insula functional circuits by varenicline and nicotine in abstinent cigarette smokers.
Topics: Adolescent; Adult; Amygdala; Benzazepines; Brain Mapping; Cerebral Cortex; Double-Blind Method; Down-Regulation; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Nicotine; Nicotinic Agonists; Quinoxalines; Rest; Smoking Cessation; Varenicline; Young Adult | 2013 |
Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal.
Topics: Adolescent; Adult; Affect; Aged; Benzazepines; Bupropion; Combined Modality Therapy; Counseling; Delayed-Action Preparations; Depression; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Treatment Outcome; Varenicline; Young Adult | 2013 |
Effect of varenicline on individual nicotine withdrawal symptoms: a combined analysis of eight randomized, placebo-controlled trials.
Topics: Adult; Aged; Benzazepines; Double-Blind Method; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Quinoxalines; Sleep Wake Disorders; Smoking Cessation; Smoking Prevention; Substance Withdrawal Syndrome; Varenicline | 2013 |
Commitment contracts and team incentives: a randomized controlled trial for smoking cessation in Thailand.
Topics: Adult; Aged; Benzazepines; Contracts; Cost-Benefit Analysis; Counseling; Female; Humans; Male; Middle Aged; Motivation; Nicotine; Quinoxalines; Rural Population; Smoking Cessation; Thailand; Time Factors; Tobacco Use Cessation Devices; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2013 |
A pragmatic, randomized, controlled study evaluating the impact of access to smoking cessation pharmacotherapy coverage on the proportion of successful quitters in a Canadian population of smokers motivated to quit (ACCESSATION).
Topics: Benzazepines; Bupropion; Canada; Female; Health Services Accessibility; Humans; Insurance, Health; Male; Middle Aged; Motivation; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Tobacco Use Cessation Devices; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2014 |
Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial.
Topics: Adult; Benzazepines; Breath Tests; Carbon Monoxide; Cholinergic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Nicotine; Quinoxalines; Smoking Cessation; Tobacco Use Cessation Devices; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2014 |
Pharmacokinetic-pharmacodynamic modeling of the effect of varenicline on nicotine craving in adult smokers.
Topics: Adolescent; Adult; Benzazepines; Craving; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Surveys and Questionnaires; Varenicline | 2015 |
Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation.
Topics: Administration, Cutaneous; Adolescent; Adult; Benzazepines; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Tobacco Use Cessation Devices; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2014 |
[Smoking cessation: varenicline/nicotine patch combination more effective than varenicline alone].
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Benzazepines; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Nicotine; Quinoxalines; Smoking Cessation; Treatment Outcome; Varenicline; Young Adult | 2014 |
Impact of cigarette smoking cessation on high-density lipoprotein functionality.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Administration, Cutaneous; Adult; Apolipoprotein A-I; Benzazepines; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholinergic Agonists; Female; Humans; Inflammation; Lipid Peroxidation; Lipids; Lipoproteins, HDL; Macrophages; Male; Malondialdehyde; Middle Aged; Nicotine; Oxidation-Reduction; Quinoxalines; Receptors, Nicotinic; Risk Factors; Smoking; Smoking Cessation; Varenicline | 2014 |
Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial.
Topics: Adult; Biomarkers; Cotinine; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Smoking Cessation; Tobacco Use Cessation Devices; Treatment Outcome; Varenicline | 2015 |
Increasing progesterone levels are associated with smoking abstinence among free-cycling women smokers who receive brief pharmacotherapy.
Topics: Adolescent; Adult; Benzazepines; Estradiol; Female; Humans; Menstrual Cycle; Middle Aged; Nicotine; Nicotinic Agonists; Progesterone; Quinoxalines; Smoking Cessation; Transdermal Patch; Treatment Outcome; Varenicline; Women's Health | 2015 |
The Nicotine Metabolite Ratio is Associated With Early Smoking Abstinence Even After Controlling for Factors That Influence the Nicotine Metabolite Ratio.
Topics: Adult; Female; Humans; Male; Middle Aged; Nicotine; Prospective Studies; Smoking; Smoking Cessation; Time Factors; Tobacco Use Cessation Devices; Tobacco Use Disorder; Varenicline | 2016 |
Effects of Nicotine Patch vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26 Weeks: A Randomized Clinical Trial.
Topics: Adult; Carbon Monoxide; Counseling; Female; Humans; Intention to Treat Analysis; Male; Medication Adherence; Middle Aged; Nicotine; Nicotinic Agonists; Outcome Assessment, Health Care; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Time Factors; Tobacco Use Cessation Devices; Varenicline | 2016 |
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Bupropion; Cohort Studies; Comorbidity; Double-Blind Method; Female; Humans; Male; Middle Aged; Mood Disorders; Nicotine; Smoking Cessation; Varenicline; Young Adult | 2016 |
Factor structure of the Smoking Cessation Self-Efficacy Questionnaire among smokers with and without a psychiatric diagnosis.
Topics: Adult; Factor Analysis, Statistical; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Outcome Assessment, Health Care; Self Efficacy; Smoking Cessation; Surveys and Questionnaires; Tobacco Use Cessation Devices; Varenicline | 2017 |
Neural Signatures of Cognitive Flexibility and Reward Sensitivity Following Nicotinic Receptor Stimulation in Dependent Smokers: A Randomized Trial.
Topics: Adult; Cerebral Cortex; Cross-Over Studies; Double-Blind Method; Executive Function; Female; Humans; Impulsive Behavior; Limbic System; Male; Motivation; Nicotine; Receptors, Nicotinic; Reversal Learning; Reward; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Cessation Devices; Tobacco Use Disorder; Varenicline | 2017 |
Effects of varenicline versus transdermal nicotine replacement therapy on cigarette demand on quit day in individuals with substance use disorders.
Topics: Administration, Cutaneous; Adult; Craving; Double-Blind Method; Female; Humans; Male; Middle Aged; Nicotine; Reinforcement, Psychology; Smoking; Smoking Cessation; Smoking Prevention; Substance-Related Disorders; Treatment Outcome; Varenicline | 2017 |
Nicotine Metabolism-informed Care for Smoking Cessation: A Pilot Precision RCT.
Topics: Adult; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Pilot Projects; Precision Medicine; Smoking Cessation; Smoking Cessation Agents; Tobacco Smoking; Tobacco Use Cessation Devices; Varenicline | 2018 |
Nicotine metabolite ratio and smoking outcomes using nicotine replacement therapy and varenicline among smokers with and without psychiatric illness.
Topics: Female; Humans; Male; Mental Disorders; Middle Aged; Nicotine; Smoking; Smoking Cessation; Smoking Cessation Agents; Time Factors; Tobacco Use Cessation Devices; Treatment Outcome; Varenicline | 2018 |
Predicting smoking abstinence with biological and self-report measures of adherence to varenicline: Impact on pharmacogenetic trial outcomes.
Topics: Adult; Female; Humans; Male; Medication Adherence; Middle Aged; Nicotine; Nicotinic Agonists; Pharmacogenetics; Predictive Value of Tests; Self Report; Smoking; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2018 |
Mediators of the effect of nicotine pre-treatment on quitting smoking.
Topics: Adult; Behavior Therapy; Bupropion; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Nicotine; Premedication; Smoking; Smoking Cessation; Smoking Cessation Agents; Tobacco Use Cessation Devices; Varenicline | 2018 |
Nicotine preloading for smoking cessation: the Preloading RCT.
Topics: Adult; Aged; Cost-Benefit Analysis; Female; Humans; Male; Middle Aged; Nicotine; Smoking Cessation; Smoking Cessation Agents; State Medicine; United Kingdom; Varenicline | 2018 |
A randomized controlled trial of 24 weeks of varenicline for tobacco use among cancer patients: Efficacy, safety, and adherence.
Topics: Adult; Benzazepines; Counseling; Female; Humans; Male; Medication Adherence; Middle Aged; Neoplasms; Nicotine; Smoking; Smoking Cessation; Smoking Cessation Agents; Substance Withdrawal Syndrome; Treatment Outcome; Varenicline | 2019 |
Anxiety Sensitivity and Distress Tolerance in Smokers: Relations With Tobacco Dependence, Withdrawal, and Quitting Success†.
Topics: Adolescent; Adult; Anxiety Disorders; Child; Ecological Momentary Assessment; Female; Humans; Male; Middle Aged; Motivation; Nicotine; Nicotinic Agonists; Smokers; Smoking Cessation; Stress, Psychological; Substance Withdrawal Syndrome; Surveys and Questionnaires; Tobacco Use Disorder; Varenicline; Young Adult | 2020 |
The Relationship of Varenicline Agonism of α4β2 Nicotinic Acetylcholine Receptors and Nicotine-Induced Dopamine Release in Nicotine-Dependent Humans.
Topics: Adolescent; Adult; Brain; Dopamine; Double-Blind Method; Female; Humans; Male; Maryland; Middle Aged; Nicotine; Nicotinic Agonists; Receptors, Nicotinic; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Varenicline; Young Adult | 2020 |
Genetic Variant in CHRNA5 and Response to Varenicline and Combination Nicotine Replacement in a Randomized Placebo-Controlled Trial.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Missouri; Nerve Tissue Proteins; Nicotine; Nicotinic Agonists; Pharmacogenetics; Pharmacogenomic Variants; Prospective Studies; Race Factors; Receptors, Nicotinic; Smokers; Smoking Cessation; Smoking Cessation Agents; Time Factors; Tobacco Use Cessation Devices; Treatment Outcome; Varenicline | 2020 |
Medication adherence and rate of nicotine metabolism are associated with response to treatment with varenicline among smokers with HIV.
Topics: Adolescent; Benzazepines; HIV Infections; Humans; Medication Adherence; Nicotine; Nicotinic Agonists; Quinoxalines; Smokers; Varenicline | 2021 |
Rationale and design of a randomized factorial clinical trial of pharmacogenetic and adherence optimization strategies to promote tobacco cessation among persons with HIV.
Topics: HIV Infections; Humans; Nicotine; Nicotinic Agonists; Pharmacogenetics; Tobacco Use Cessation; Varenicline | 2021 |
Time-Varying Mediation of Pharmacological Smoking Cessation Treatments on Smoking Lapse via Craving, Cessation Fatigue, and Negative Mood.
Topics: Craving; Fatigue; Humans; Nicotine; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Smoking; Varenicline | 2022 |
Cytisine Therapy Improved Smoking Cessation in the Randomized Screening and Multiple Intervention on Lung Epidemics Lung Cancer Screening Trial.
Topics: Alkaloids; Azocines; Early Detection of Cancer; Humans; Lung; Lung Neoplasms; Nicotine; Quinolizines; Smoking Cessation; Varenicline | 2022 |
Effectiveness of Varenicline and Cytisine for Alcohol Use Reduction Among People With HIV and Substance Use: A Randomized Clinical Trial.
Topics: Adult; Alcoholism; Alkaloids; Azocines; Benzazepines; Female; HIV Infections; Humans; Male; Nicotine; Nicotinic Agonists; Quinolizines; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline | 2022 |
Influence of CYP2A6 Genetic Variation, Nicotine Dependence Severity, and Treatment on Smoking Cessation Success.
Topics: Adult; Cytochrome P-450 CYP2A6; Female; Genetic Variation; Humans; Male; Nicotine; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2023 |
Glucagon-like peptide-1 analogues: a new way to quit smoking? (SKIP)-a structured summary of a study protocol for a randomized controlled study.
Topics: Double-Blind Method; Glucagon-Like Peptide 1; Humans; Nicotine; Randomized Controlled Trials as Topic; Smoking Cessation; Substance Withdrawal Syndrome; Varenicline; Weight Gain | 2023 |
Cytisine Versus Varenicline for Smoking Cessation in a Primary Care Setting: A Randomized Non-inferiority Trial.
Topics: Alkaloids; Azocines; Benzazepines; Humans; Nicotine; Nicotinic Agonists; Primary Health Care; Quinolizines; Smoking Cessation; Treatment Outcome; Varenicline | 2023 |
Multiple Pharmacotherapy Adaptations for Smoking Cessation Based on Treatment Response in Black Adults Who Smoke: A Randomized Clinical Trial.
Topics: Adult; Bupropion; Ethnicity; Female; Humans; Male; Middle Aged; Minority Groups; Nicotine; Smoking; Smoking Cessation; Varenicline | 2023 |
Adaptive Smoking Cessation Using Precessation Varenicline or Nicotine Patch: A Randomized Clinical Trial.
Topics: Bupropion; COVID-19; Female; Humans; Male; Middle Aged; Nicotine; Pandemics; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline | 2023 |
Effectiveness of nicotine salt vapes, cytisine, and a combination of these products, for smoking cessation in New Zealand: protocol for a three-arm, pragmatic, community-based randomised controlled trial.
Topics: Electronic Nicotine Delivery Systems; Humans; New Zealand; Nicotine; Quality of Life; Randomized Controlled Trials as Topic; Smoking Cessation; Sodium Chloride, Dietary; Tobacco Use Cessation Devices; Vaping; Varenicline | 2023 |
The impact of blunt use on smoking abstinence among Black adults: Secondary analysis from randomized controlled smoking cessation clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Black or African American; Female; Humans; Male; Middle Aged; Nicotine; Smoking; Smoking Cessation; Varenicline; Young Adult | 2024 |
213 other study(ies) available for nicotine and varenicline
| Article | Year |
|---|---|
3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation.
Topics: Animals; Cyclization; Molecular Structure; Piperidines; Rats; Receptors, Nicotinic; Smoking Cessation; Structure-Activity Relationship | 2005 |
Synthesis, nicotinic acetylcholine receptor binding, and pharmacological properties of 3'-(substituted phenyl)deschloroepibatidine analogs.
Topics: Analgesics; Animals; Body Temperature; Bridged Bicyclo Compounds, Heterocyclic; Cerebral Cortex; Disease Models, Animal; Dose-Response Relationship, Drug; Mice; Molecular Structure; Nicotinic Antagonists; Pain; Protein Binding; Pyridines; Radioligand Assay; Receptors, Nicotinic; Structure-Activity Relationship | 2008 |
Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 3'-(substituted phenyl)epibatidine analogues. Nicotinic partial agonists.
Topics: Analgesics; Animals; Bridged Bicyclo Compounds, Heterocyclic; Male; Mice; Molecular Structure; Nicotinic Agonists; Pyridines; Rats; Receptors, Nicotinic | 2010 |
A novel series of [3.2.1] azabicyclic biaryl ethers as alpha3beta4 and alpha6/4beta4 nicotinic receptor agonists.
Topics: Azabicyclo Compounds; Nicotinic Agonists; Receptors, Nicotinic; Structure-Activity Relationship; Sulfonamides | 2010 |
Unichiral 2-(2'-pyrrolidinyl)-1,4-benzodioxanes: the 2R,2'S diastereomer of the N-methyl-7-hydroxy analogue is a potent α4β2- and α6β2-nicotinic acetylcholine receptor partial agonist.
Topics: Animals; Binding Sites; Cerebral Cortex; Corpus Striatum; Dioxanes; Dopamine; Drug Partial Agonism; HEK293 Cells; Humans; In Vitro Techniques; Male; Models, Molecular; Nicotinic Agonists; Pyrrolidines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Stereoisomerism; Structure-Activity Relationship | 2011 |
Identification of novel α4β2-nicotinic acetylcholine receptor (nAChR) agonists based on an isoxazole ether scaffold that demonstrate antidepressant-like activity.
Topics: Animals; Antidepressive Agents; Blood Proteins; Cytochrome P-450 Enzyme Inhibitors; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; HEK293 Cells; Humans; Isoxazoles; Male; Mice; Mice, Inbred BALB C; Microsomes, Liver; Nicotinic Agonists; Protein Binding; Radioligand Assay; Rats; Receptors, Nicotinic; Stereoisomerism; Structure-Activity Relationship | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Synthesis and nicotinic receptor activity of chemical space analogues of N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-4-chlorobenzamide (PNU-282,987) and 1,4-diazabicyclo[3.2.2]nonane-4-carboxylic acid 4-bromophenyl ester (SSR180711).
Topics: Allosteric Regulation; Animals; Benzamides; Binding Sites; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, Heterocyclic; Databases, Factual; Female; Humans; Models, Molecular; Nicotinic Agonists; Nicotinic Antagonists; Oocytes; Patch-Clamp Techniques; Receptors, Nicotinic; Stereoisomerism; Structure-Activity Relationship; Xenopus | 2012 |
Structure-activity studies of 7-heteroaryl-3-azabicyclo[3.3.1]non-6-enes: a novel class of highly potent nicotinic receptor ligands.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Calcium; Cells, Cultured; Electrophysiology; Humans; Kidney; Ligands; Molecular Structure; Neuroblastoma; Nicotine; Protein Subunits; Receptors, Nicotinic; Stereoisomerism; Structure-Activity Relationship | 2012 |
Discovery of highly potent and selective α4β2-nicotinic acetylcholine receptor (nAChR) partial agonists containing an isoxazolylpyridine ether scaffold that demonstrate antidepressant-like activity. Part II.
Topics: Animals; Antidepressive Agents; Humans; Isoxazoles; Male; Mice; Mice, Inbred BALB C; Motor Activity; Neuroblastoma; Nicotinic Agonists; Protein Binding; Radioligand Assay; Receptors, Nicotinic; Stereoisomerism; Structure-Activity Relationship; Swimming | 2012 |
Chemistry and pharmacological studies of 3-alkoxy-2,5-disubstituted-pyridinyl compounds as novel selective α4β2 nicotinic acetylcholine receptor ligands that reduce alcohol intake in rats.
Topics: Alcohol Drinking; Animals; Ethanol; Ferrets; Ligands; Magnetic Resonance Spectroscopy; Pyridines; Rats; Receptors, Nicotinic; Spectrometry, Mass, Electrospray Ionization | 2013 |
Design, synthesis and discovery of picomolar selective α4β2 nicotinic acetylcholine receptor ligands.
Topics: Azetidines; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Discovery; Humans; Ligands; Models, Molecular; Molecular Structure; Pyridines; Receptors, Nicotinic; Software; Structure-Activity Relationship | 2013 |
Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2'-fluoro-3'-(substituted pyridinyl)-7-deschloroepibatidine analogues.
Topics: Analgesics; Animals; Body Temperature; Bridged Bicyclo Compounds, Heterocyclic; Contraindications; Female; Male; Mice; Nicotinic Agonists; Nicotinic Antagonists; Oocytes; Pain; Patch-Clamp Techniques; Pyridines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Structure-Activity Relationship; Xenopus | 2014 |
Enantiopure Cyclopropane-Bearing Pyridyldiazabicyclo[3.3.0]octanes as Selective α4β2-nAChR Ligands.
Topics: | 2014 |
Synthesis, nicotinic acetylcholine receptor binding, in vitro and in vivo pharmacology properties of 3'-(substituted pyridinyl)-deschloroepibatidine analogs.
Topics: Animals; Bridged Bicyclo Compounds, Heterocyclic; Humans; Mice; Molecular Structure; Nicotiana; Pyridines; Rats; Receptors, Nicotinic; Structure-Activity Relationship | 2015 |
[Medication for ending tobacco dependency. Current state].
Topics: Antidepressive Agents, Second-Generation; Benzazepines; Bupropion; Cannabinoid Receptor Antagonists; Humans; Nicotine; Piperidines; Pyrazoles; Quinoxalines; Receptors, Nicotinic; Rimonabant; Smoking Cessation; Time Factors; Tobacco Use Disorder; Varenicline | 2005 |
Ligands selective for alpha4beta2 but not alpha3beta4 or alpha7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Appetitive Behavior; Azetidines; Benzazepines; Corpus Striatum; Cystine; Discrimination Learning; Dose-Response Relationship, Drug; Male; Motivation; Nicotine; Nicotinic Agonists; Pyridines; Quinoxalines; Rats; Rats, Inbred Strains; Receptors, Nicotinic; Tobacco Use Disorder; Varenicline | 2007 |
Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.
Topics: Animals; Behavior, Animal; Benzazepines; Brain; Cell Line, Transformed; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; In Vitro Techniques; Male; Membrane Potentials; Nicotine; Nicotinic Agonists; Patch-Clamp Techniques; Protein Binding; Quinoxalines; Rats; Rats, Long-Evans; Rats, Sprague-Dawley; Self Administration; Smoking Cessation; Transfection; Varenicline | 2007 |
[The path from cigarettes--with support it works better].
Topics: Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Varenicline | 2007 |
Exacerbation of schizophrenia by varenicline.
Topics: Acute Disease; Benzazepines; Cognition Disorders; Comorbidity; Female; Humans; Middle Aged; Nicotine; Quinoxalines; Recurrence; Schizophrenia; Schizophrenic Psychology; Self Medication; Smoking; Smoking Cessation; Varenicline | 2007 |
Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzazepines; Bupropion; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Male; Middle Aged; Models, Theoretical; Netherlands; Nicotine; Nortriptyline; Quality of Life; Quinoxalines; Smoking; Smoking Cessation; Varenicline | 2008 |
Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness.
Topics: Adult; Benzazepines; Cohort Studies; Drug Combinations; Female; Follow-Up Studies; Humans; London; Male; Mental Disorders; Middle Aged; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2008 |
[New drugs; varenicline].
Topics: Benzazepines; Humans; Nausea; Nicotine; Nicotinic Agonists; Quinoxalines; Receptors, Nicotinic; Smoking Cessation; Varenicline | 2007 |
The truth about smoking cessation.
Topics: Antidepressive Agents, Second-Generation; Benzazepines; Bupropion; Counseling; Humans; Middle Aged; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Varenicline | 2007 |
Breaking away from a narrow prescribing protocol for medicinal nicotine.
Topics: Administration, Cutaneous; Adult; Benzazepines; Humans; Nicotine; Nicotinic Agonists; Patient Acceptance of Health Care; Quinoxalines; Smoking Cessation; Substance Withdrawal Syndrome; Varenicline | 2008 |
Stat bite: Medicaid coverage of tobacco-dependence treatments.
Topics: Administration, Cutaneous; Administration, Intranasal; Administration, Oral; Antidepressive Agents, Second-Generation; Benzazepines; Bupropion; Counseling; Dopamine Uptake Inhibitors; Female; Humans; Insurance Coverage; Male; Medicaid; Nicotine; Nicotinic Agonists; Pregnancy; Pregnancy Complications; Quinoxalines; Tobacco Use Disorder; United States; Varenicline | 2008 |
Smoking cessation 2008.
Topics: Benzazepines; Cannabinoid Receptor Antagonists; Drug Prescriptions; Humans; Marketing of Health Services; Nicotine; Nicotinic Agonists; Piperidines; Pyrazoles; Quinoxalines; Rimonabant; Smoking; Smoking Cessation; Smoking Prevention; Vaccines; Varenicline | 2008 |
Pharmacological effects of nicotine on norepinephrine metabolism in rat brown adipose tissue: relevance to nicotinic therapies for smoking cessation.
Topics: Adipose Tissue, Brown; Animals; Benzazepines; Dose-Response Relationship, Drug; Female; Lipoma; Male; Mediastinal Neoplasms; Nicotine; Nicotinic Agonists; Norepinephrine; Quinoxalines; Rats; Rats, Sprague-Dawley; Sex Factors; Smoking Cessation; Varenicline | 2008 |
Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers.
Topics: Adolescent; Adult; Benzazepines; Bupropion; Costs and Cost Analysis; Drug Costs; Female; Humans; Male; Markov Chains; Middle Aged; Models, Statistical; Nicotine; Quinoxalines; Smoking; Smoking Cessation; United States; Varenicline | 2008 |
Pre-cessation varenicline treatment vs post-cessation NRT: an uneven playing field.
Topics: Benzazepines; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Smoking Prevention; Varenicline | 2008 |
Clinically significant outcomes in smoking cessation.
Topics: Benzazepines; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Smoking Prevention; Treatment Outcome; Varenicline | 2008 |
Effect of varenicline on the acute and repeated locomotor responses to nicotine in rats.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Benzazepines; Drug Administration Schedule; Male; Motor Activity; Nicotine; Quinoxalines; Rats; Rats, Wistar; Receptors, Nicotinic; Varenicline | 2008 |
Effects of the nicotinic receptor partial agonists varenicline and cytisine on the discriminative stimulus effects of nicotine in rats.
Topics: Alkaloids; Animals; Azocines; Benzazepines; Conditioning, Operant; Data Interpretation, Statistical; Discrimination, Psychological; Dose-Response Relationship, Drug; Generalization, Stimulus; Male; Nicotine; Nicotinic Agonists; Quinolizines; Quinoxalines; Rats; Rats, Long-Evans; Receptors, Nicotinic; Varenicline | 2009 |
An algorithm for tailoring pharmacotherapy for smoking cessation: results from a Delphi panel of international experts.
Topics: Algorithms; Behavior Therapy; Benzazepines; Bupropion; Combined Modality Therapy; Consensus; Decision Support Techniques; Delphi Technique; Humans; Nicotine; Nicotinic Agonists; Practice Patterns, Physicians'; Quinoxalines; Smoking Cessation; Varenicline | 2009 |
Targeting reward-relevant nicotinic receptors in the discovery of novel pharmacotherapeutic agents to treat tobacco dependence.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Benzazepines; Brain; Bupropion; Dopamine; Dose-Response Relationship, Drug; Drugs, Investigational; Male; Neurons; Nicotine; Nicotinic Antagonists; Picolines; Quaternary Ammonium Compounds; Quinoxalines; Rats; Rats, Inbred F344; Rats, Sprague-Dawley; Receptors, Nicotinic; Reward; Smoking Cessation; Structure-Activity Relationship; Tobacco Use Disorder; Varenicline; Ventral Tegmental Area | 2009 |
[Drug treatment for smoking and marijuana abuse].
Topics: Antidepressive Agents, Second-Generation; Benzazepines; Humans; Marijuana Abuse; Nicotine; Nicotinic Agonists; Quinoxalines; Receptors, Nicotinic; Smoking Cessation; Varenicline | 2008 |
The smoking cessation medication varenicline attenuates alcohol and nicotine interactions in the rat mesolimbic dopamine system.
Topics: Animals; Benzazepines; Central Nervous System Depressants; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Ethanol; Limbic System; Male; Microdialysis; Nicotine; Nucleus Accumbens; Quinoxalines; Rats; Rats, Wistar; Smoking Cessation; Varenicline | 2009 |
Do implementation issues influence the effectiveness of medications? The case of nicotine replacement therapy and bupropion in UK Stop Smoking Services.
Topics: Administration, Cutaneous; Adult; Benzazepines; Bupropion; Cohort Studies; Community Health Services; Female; Follow-Up Studies; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Nicotine; Nicotinic Agonists; Patient Participation; Probability; Program Evaluation; Quinoxalines; Randomized Controlled Trials as Topic; Risk Factors; Smoking; Smoking Cessation; Smoking Prevention; Treatment Outcome; United Kingdom; Varenicline; Young Adult | 2009 |
A reader responds to "Seven pharmacotherapies do promote smoking abstinence at 6 and 12 months".
Topics: Administration, Cutaneous; Administration, Inhalation; Administration, Oral; Benzazepines; Bupropion; Chewing Gum; Female; Follow-Up Studies; Humans; Male; Multivariate Analysis; Nicotine; Nicotinic Agonists; Patient Compliance; Probability; Quebec; Quinoxalines; Risk Assessment; Smoking; Smoking Cessation; Smoking Prevention; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2008 |
Combination treatment with varenicline and nicotine replacement therapy.
Topics: Adult; Aged; Benzazepines; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Outcome Assessment, Health Care; Quinoxalines; Smoking Cessation; Varenicline | 2009 |
Varenicline attenuates nicotine-enhanced brain-stimulation reward by activation of alpha4beta2 nicotinic receptors in rats.
Topics: Animals; Benzazepines; Conditioning, Operant; Dose-Response Relationship, Drug; Drug Interactions; Electric Stimulation; Male; Medial Forebrain Bundle; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Quinoxalines; Rats; Rats, Long-Evans; Receptors, Nicotinic; Reward; Varenicline | 2009 |
Treatment of comorbid tobacco use in people with serious mental illness.
Topics: Adult; Benzazepines; Bupropion; Comorbidity; Counseling; Dopamine Uptake Inhibitors; Female; Follow-Up Studies; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Schizophrenia, Paranoid; Smoking; Smoking Cessation; Varenicline | 2009 |
Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation--results from four European countries.
Topics: Adolescent; Adult; Aged; Benzazepines; Cost-Benefit Analysis; Europe; Female; Heart Diseases; Humans; Incidence; Lung Neoplasms; Male; Markov Chains; Middle Aged; Models, Statistical; Nicotine; Nicotinic Agonists; Pulmonary Disease, Chronic Obstructive; Quality-Adjusted Life Years; Quinoxalines; Smoking; Smoking Cessation; Stroke; Varenicline; Young Adult | 2009 |
[Current and future medical drugs for smoking cessation].
Topics: Adrenergic alpha-Agonists; Antidepressive Agents; Behavior Therapy; Benzazepines; Bupropion; Cannabinoid Receptor Antagonists; Clinical Trials as Topic; Clonidine; Combined Modality Therapy; Counseling; Humans; Nicotine; Nicotinic Agonists; Nortriptyline; Piperidines; Pyrazoles; Quinoxalines; Rimonabant; Smoking Cessation; Tobacco Use Disorder; Vaccines; Varenicline | 2009 |
Cost-effectiveness of varenicline for smoking cessation.
Topics: Benzazepines; Bupropion; Clinical Trials as Topic; Cost Savings; Cost-Benefit Analysis; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Smoking Prevention; Varenicline | 2009 |
Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis.
Topics: Adolescent; Adult; Age Factors; Aged; Antidepressive Agents, Second-Generation; Belgium; Benzazepines; Bupropion; Computer Simulation; Cost-Benefit Analysis; Counseling; Female; Humans; Male; Markov Chains; Middle Aged; Models, Statistical; Nicotine; Nicotinic Agonists; Quinoxalines; Recurrence; Smoking; Smoking Cessation; Treatment Outcome; Varenicline; Young Adult | 2009 |
Smoking cessation: how to advise the patient.
Topics: Ambulatory Care; Behavior Therapy; Benzazepines; Bupropion; Counseling; Dopamine Uptake Inhibitors; Humans; Motivation; Nicotine; Nicotinic Agonists; Patient Education as Topic; Physician-Patient Relations; Quinoxalines; Secondary Prevention; Smoking Cessation; Smoking Prevention; Varenicline | 2009 |
Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzazepines; Bupropion; Cohort Studies; Dopamine Uptake Inhibitors; Family Practice; Female; Ganglionic Stimulants; Humans; Male; Middle Aged; Nicotine; Quinoxalines; Smoking Cessation; Suicide; Varenicline; Young Adult | 2009 |
Effect of the alpha4beta2* nicotinic acetylcholine receptor partial agonist varenicline on dopamine release in beta2 knock-out mice with selective re-expression of the beta2 subunit in the ventral tegmental area.
Topics: Animals; Benzazepines; Dopamine; Extracellular Space; Genetic Vectors; Green Fluorescent Proteins; Lentivirus; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Microdialysis; Nicotine; Nicotinic Agonists; Nucleus Accumbens; Quinoxalines; Receptors, Nicotinic; Varenicline | 2010 |
[Drug treatment of tobacco dependence].
Topics: Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Humans; Meta-Analysis as Topic; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2009 |
The alpha4beta2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats.
Topics: Animals; Association Learning; Behavior, Animal; Benzazepines; Conditioning, Operant; Cues; Dose-Response Relationship, Drug; Exploratory Behavior; Food; Male; Models, Animal; Nicotine; Nicotinic Agonists; Quinoxalines; Rats; Receptors, Nicotinic; Recurrence; Reinforcement, Psychology; Self Administration; Tobacco Use Disorder; Varenicline | 2010 |
Effects of varenicline and mecamylamine on the acquisition, expression, and reinstatement of nicotine-conditioned place preference by drug priming in rats.
Topics: Animals; Benzazepines; Conditioning, Classical; Dose-Response Relationship, Drug; Male; Mecamylamine; Morphine; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Quinoxalines; Rats; Rats, Wistar; Receptors, Nicotinic; Reward; Tobacco Use Disorder; Varenicline | 2010 |
Extinction with varenicline and nornicotine, but not ABT-418, weakens conditioned responding evoked by the interoceptive stimulus effects of nicotine.
Topics: Animals; Benzazepines; Conditioning, Classical; Discrimination, Psychological; Extinction, Psychological; Generalization, Psychological; Isoxazoles; Ligands; Male; Nicotine; Nicotinic Agonists; Pyrrolidines; Quinoxalines; Rats; Rats, Sprague-Dawley; Varenicline | 2010 |
Varenicline treatment decreases DNMT1 mRNA expression in lymphocytes of schizophrenic patients who are cigarette smokers.
Topics: Benzazepines; Cotinine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Gene Expression; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; RNA, Messenger; Schizophrenia; Smoking Cessation; Varenicline | 2010 |
Characteristics and abstinence outcomes among tobacco quitline enrollees using varenicline or nicotine replacement therapy.
Topics: Adolescent; Adult; Benzazepines; Counseling; Female; Humans; Male; Montana; Nicotine; Nicotinic Agonists; Quinoxalines; Retrospective Studies; Smoking Cessation; Telephone; Tobacco Use Disorder; Treatment Outcome; Varenicline; Young Adult | 2010 |
Nicotinic partial agonists varenicline and sazetidine-A have differential effects on affective behavior.
Topics: Animals; Anxiety; Azetidines; Behavior, Animal; Benzazepines; Chimera; Depression; Drug Partial Agonism; Male; Mice; Mood Disorders; Nicotine; Nicotinic Agonists; Pyridines; Quinoxalines; Varenicline | 2010 |
Varenicline and mecamylamine attenuate locomotor sensitization and cross-sensitization induced by nicotine and morphine in mice.
Topics: Analgesics, Opioid; Animals; Benzazepines; Dose-Response Relationship, Drug; Drug Interactions; Male; Mecamylamine; Mice; Morphine; Motor Activity; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Quinoxalines; Varenicline | 2010 |
Current treatment options in smoking cessation.
Topics: Adrenergic alpha-Agonists; Antidepressive Agents; Behavior Therapy; Benzazepines; Bupropion; Clonidine; Combined Modality Therapy; Counseling; Humans; Nicotine; Nicotinic Agonists; Nortriptyline; Patient Selection; Piperidines; Practice Guidelines as Topic; Pyrazoles; Quinoxalines; Rimonabant; Self-Help Groups; Smoking Cessation; Tobacco Use Disorder; United States; Vaccines; Varenicline | 2010 |
The use of snus for quitting smoking compared with medicinal products.
Topics: Adult; Benzazepines; Chewing Gum; Data Collection; Humans; Male; Middle Aged; Nicotine; Quinoxalines; Regression Analysis; Smoking Cessation; Tobacco, Smokeless; Varenicline | 2010 |
[The management of patients with nicotine dependence - the role of the general practitioners].
Topics: Behavior Therapy; Benzazepines; Bupropion; Combined Modality Therapy; Disease Management; Dopamine Uptake Inhibitors; Family Practice; Humans; Motivation; Nicotine; Nicotinic Agonists; Physician-Patient Relations; Quinoxalines; Secondary Prevention; Smoking Cessation; Switzerland; Tobacco Use Disorder; Varenicline | 2010 |
[Medical therapy for smoking cessation].
Topics: Administration, Cutaneous; Administration, Inhalation; Administration, Oral; Antidepressive Agents; Benzazepines; Bupropion; Chewing Gum; Drug Therapy, Combination; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2010 |
Varenicline blocks nicotine intake in rats with extended access to nicotine self-administration.
Topics: Animals; Benzazepines; Dose-Response Relationship, Drug; Male; Motivation; Nicotine; Nicotinic Agonists; Quinoxalines; Rats; Rats, Wistar; Receptors, Nicotinic; Reinforcement, Psychology; Self Administration; Varenicline | 2011 |
Abstinence and psychological distress in co-morbid smokers using various pharmacotherapies.
Topics: Adult; Aged; Benzazepines; Bupropion; Cohort Studies; Comorbidity; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Nicotine; Quinoxalines; Retrospective Studies; Smoking; Smoking Cessation; Stress, Psychological; Treatment Outcome; Varenicline; Young Adult | 2011 |
The sensitizing effect of acute nicotine on amphetamine-stimulated behavior and dopamine efflux requires activation of β2 subunit-containing nicotinic acetylcholine receptors and glutamate N-methyl-D-aspartate receptors.
Topics: Aconitine; Amphetamine; Animals; Behavior, Animal; Benzazepines; Central Nervous System Stimulants; Dizocilpine Maleate; Dopamine; Excitatory Amino Acid Antagonists; Female; Male; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Receptors, Nicotinic; Varenicline | 2011 |
Parallel anxiolytic-like effects and upregulation of neuronal nicotinic acetylcholine receptors following chronic nicotine and varenicline.
Topics: Animals; Benzazepines; Cerebral Cortex; Hippocampus; Male; Mice; Nicotine; Quinoxalines; Receptors, Nicotinic; Smoking Cessation; Substance Withdrawal Syndrome; Thalamus; Up-Regulation; Varenicline | 2011 |
Adherence to and reasons for premature discontinuation from stop-smoking medications: data from the ITC Four-Country Survey.
Topics: Adolescent; Adult; Aged; Australia; Benzazepines; Bupropion; Canada; Cohort Studies; Data Collection; Female; Humans; Male; Medication Adherence; Middle Aged; Nicotine; Nonprescription Drugs; Prescription Drugs; Prevalence; Quinoxalines; Smoking Cessation; Time Factors; Tobacco Use Disorder; Treatment Outcome; United Kingdom; United States; Varenicline; Young Adult | 2011 |
The effects of nicotine, varenicline, and cytisine on schedule-controlled responding in mice: differences in α4β2 nicotinic receptor activation.
Topics: Alkaloids; Animals; Azocines; Benzazepines; Conditioning, Operant; Dihydro-beta-Erythroidine; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Male; Mecamylamine; Mice; Mice, Inbred C57BL; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Quinolizines; Quinoxalines; Receptors, Nicotinic; Reinforcement Schedule; Smoking Cessation; Time Factors; Varenicline | 2011 |
Integrating results from smoking cessation drug research and development into clinical occupational health practice.
Topics: Benzazepines; Bupropion; Humans; Nicotine; Nicotinic Agonists; Occupational Health Nursing; Practice Guidelines as Topic; Quinoxalines; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2011 |
Electrophysiological perspectives on the therapeutic use of nicotinic acetylcholine receptor partial agonists.
Topics: Acetylcholine; Alkaloids; alpha7 Nicotinic Acetylcholine Receptor; Animals; Azocines; Benzazepines; Bupropion; DNA, Complementary; Dopamine Uptake Inhibitors; Electrophysiological Phenomena; Humans; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Oocytes; Pyridinium Compounds; Quinolizines; Quinoxalines; Receptors, Nicotinic; Smoking Cessation; Varenicline; Xenopus | 2011 |
Varenicline attenuates cue-induced relapse to alcohol, but not nicotine seeking, while reducing inhibitory response control.
Topics: Animals; Behavior, Animal; Benzazepines; Conditioning, Operant; Cues; Dose-Response Relationship, Drug; Ethanol; Male; Nicotine; Nicotinic Agonists; Quinoxalines; Rats; Rats, Wistar; Reaction Time; Recurrence; Reinforcement Schedule; Self Administration; Sucrose; Varenicline | 2011 |
Selective α4β2 nicotinic acetylcholine receptor agonists target epigenetic mechanisms in cortical GABAergic neurons.
Topics: Analysis of Variance; Animals; Azetidines; Behavior, Animal; Benzazepines; Cerebral Cortex; Conditioning, Classical; Cues; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Epigenomics; Exploratory Behavior; Fear; Freezing Reaction, Cataleptic; gamma-Aminobutyric Acid; Gene Expression Regulation; Glutamate Decarboxylase; Male; Mecamylamine; Methyl-CpG-Binding Protein 2; Mice; Neurons; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Promoter Regions, Genetic; Quinoxalines; Receptors, Nicotinic; RNA, Messenger; Varenicline | 2011 |
[Abstinence rates with varenicline compared to bupropion and nicotine replacement therapy for quitting smoking in primary care].
Topics: Adolescent; Adult; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Female; Humans; Longitudinal Studies; Male; Middle Aged; Nicotine; Nicotinic Agonists; Primary Health Care; Quinoxalines; Retrospective Studies; Smoking Cessation; Substance Withdrawal Syndrome; Varenicline; Young Adult | 2011 |
Varenicline, a partial agonist at neuronal nicotinic acetylcholine receptors, reduces nicotine-induced increases in 20% ethanol operant self-administration in Sprague-Dawley rats.
Topics: Alcohol Drinking; Animals; Benzazepines; Choice Behavior; Conditioning, Operant; Dose-Response Relationship, Drug; Male; Neurons; Nicotine; Nicotinic Agonists; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Self Administration; Stimulation, Chemical; Varenicline | 2011 |
Prescribing of smoking cessation medication in England since the introduction of varenicline.
Topics: Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Drug Prescriptions; Electronic Health Records; England; Family Practice; Humans; Models, Statistical; Nicotine; Nicotinic Agonists; Practice Guidelines as Topic; Practice Patterns, Physicians'; Quinoxalines; Smoking; Smoking Cessation; Smoking Prevention; State Medicine; Time Factors; Varenicline | 2011 |
Smoking cessation interventions: a primer for physicians: Comment on "Use of varenicline for 4 weeks before quitting smoking".
Topics: Benzazepines; Bupropion; Chewing Gum; Counseling; Delayed-Action Preparations; Drug Administration Schedule; Drug Therapy, Combination; Humans; Nasal Sprays; Nebulizers and Vaporizers; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Smoking Prevention; Substance Withdrawal Syndrome; Time Factors; Transdermal Patch; Treatment Outcome; Varenicline | 2011 |
A comparison of brain and behavioral effects of varenicline and nicotine in rats.
Topics: Animals; Benzazepines; Brain; Brain Mapping; Drug Administration Schedule; Drug Tolerance; Injections, Intravenous; Injections, Subcutaneous; Magnetic Resonance Imaging; Male; Maze Learning; Motor Activity; Nicotine; Nicotinic Agonists; Quinoxalines; Rats; Rats, Sprague-Dawley; Varenicline | 2011 |
Cost effectiveness of interventions to reduce relapse to smoking following smoking cessation.
Topics: Benzazepines; Bupropion; Cost-Benefit Analysis; Dopamine Uptake Inhibitors; England; Epidemiologic Methods; Health Care Costs; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Secondary Prevention; Smoking; Smoking Cessation; Treatment Outcome; Varenicline; Wales | 2011 |
The impact of the introduction of smoke-free legislation on prescribing of stop-smoking medications in England.
Topics: Adolescent; Adult; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Drug Prescriptions; Electronic Health Records; England; Family Practice; Female; Humans; Male; Middle Aged; Models, Statistical; Nicotine; Nicotinic Agonists; Practice Patterns, Physicians'; Quinoxalines; Smoking; Smoking Cessation; State Medicine; Time Factors; Varenicline; Young Adult | 2011 |
Smoking cessation pharmacotherapy: a concise overview.
Topics: Adrenergic alpha-2 Receptor Agonists; Antidepressive Agents; Benzazepines; Bupropion; Clonidine; Humans; Nicotine; Nicotinic Agonists; Nortriptyline; Quinoxalines; Smoking; Smoking Cessation; Varenicline | 2011 |
Assessing preferences for improved smoking cessation medications: a discrete choice experiment.
Topics: Adolescent; Adult; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Female; Humans; Logistic Models; Male; Middle Aged; Models, Econometric; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Substance-Related Disorders; Surveys and Questionnaires; Switzerland; Varenicline; Young Adult | 2012 |
Patterns of nicotinic receptor antagonism: nicotine discrimination studies.
Topics: Animals; Benzazepines; Bridged Bicyclo Compounds, Heterocyclic; Cytosine; Data Interpretation, Statistical; Dihydro-beta-Erythroidine; Discrimination Learning; Discrimination, Psychological; Dose-Response Relationship, Drug; Male; Mecamylamine; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Pyridines; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Varenicline | 2011 |
Breaking free from nicotine dependence. A combination of strategies boosts the odds of success.
Topics: Administration, Cutaneous; Administration, Intranasal; Adult; Antidepressive Agents, Second-Generation; Behavior Therapy; Benzazepines; Bupropion; Cognitive Behavioral Therapy; Cross-Sectional Studies; Female; Humans; Male; Nicotine; Nicotinic Agonists; Quinoxalines; Self-Help Groups; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2011 |
Effects of varenicline on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys.
Topics: Animals; Benzazepines; Cocaine; Cocaine-Related Disorders; Conditioning, Operant; Discrimination Learning; Discrimination, Psychological; Dopamine Uptake Inhibitors; Macaca mulatta; Male; Mecamylamine; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Quinoxalines; Reinforcement, Psychology; Self Administration; Time Factors; Varenicline | 2011 |
[Clinical study of smoking cessation clinic subjects].
Topics: Adult; Aged; Aged, 80 and over; Benzazepines; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Outpatient Clinics, Hospital; Outpatients; Quinoxalines; Smoking Cessation; Varenicline | 2011 |
Varenicline decreases nicotine self-administration and cue-induced reinstatement of nicotine-seeking behaviour in rats when a long pretreatment time is used.
Topics: Animals; Benzazepines; Conditioning, Operant; Cues; Data Interpretation, Statistical; Discrimination, Psychological; Dose-Response Relationship, Drug; Drug-Seeking Behavior; Feeding Behavior; Male; Motivation; Nicotine; Quinoxalines; Rats; Rats, Long-Evans; Rats, Sprague-Dawley; Reinforcement Schedule; Self Administration; Tobacco Use Disorder; Varenicline | 2012 |
[Smoking cessation--assistance for the general practitioner].
Topics: Benzazepines; Bupropion; Combined Modality Therapy; Complementary Therapies; Cost-Benefit Analysis; Drug Costs; Fee Schedules; Germany; Humans; Myocardial Infarction; National Health Programs; Nicotine; Nicotinic Agonists; Physician's Role; Polymethacrylic Acids; Polyvinyls; Psychotherapy, Group; Quinoxalines; Smoking Cessation; Social Support; Tobacco Use Cessation Devices; Tobacco Use Disorder; Varenicline | 2011 |
Varenicline dose dependently enhances responding for nonpharmacological reinforcers and attenuates the reinforcement-enhancing effects of nicotine.
Topics: Animals; Benzazepines; Dose-Response Relationship, Drug; Male; Nicotine; Nicotinic Agonists; Quinoxalines; Rats; Rats, Sprague-Dawley; Reinforcement, Psychology; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2012 |
Quantification of nicotine, cotinine, trans-3'-hydroxycotinine and varenicline in human plasma by a sensitive and specific UPLC-tandem mass-spectrometry procedure for a clinical study on smoking cessation.
Topics: Benzazepines; Chromatography, High Pressure Liquid; Cotinine; Drug Stability; Humans; Linear Models; Nicotine; Quinoxalines; Reproducibility of Results; Sensitivity and Specificity; Smoking Cessation; Tandem Mass Spectrometry; Varenicline | 2011 |
Suicidal behavior and depression in smoking cessation treatments.
Topics: Adult; Benzazepines; Bupropion; Depression; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Suicide; Varenicline | 2011 |
Varenicline blocks β2*-nAChR-mediated response and activates β4*-nAChR-mediated responses in mice in vivo.
Topics: Animals; Benzazepines; Dose-Response Relationship, Drug; Female; Genotype; Hexamethonium; Hypothermia; Inhibitory Concentration 50; Male; Mecamylamine; Mice; Mice, Inbred C57BL; Motor Activity; Mutation; Nerve Tissue Proteins; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Ondansetron; Quinoxalines; Receptors, Nicotinic; Receptors, Serotonin, 5-HT3; Varenicline | 2012 |
Effects of the combination of metyrapone and oxazepam on intravenous nicotine self-administration in rats.
Topics: Animals; Benzazepines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors; Hypnotics and Sedatives; Infusions, Intravenous; Male; Metyrapone; Nicotine; Oxazepam; Quinoxalines; Rats; Rats, Wistar; Reinforcement Schedule; Self Administration; Smoking Cessation; Varenicline | 2012 |
Pharmacologic characterization of a nicotine-discriminative stimulus in rhesus monkeys.
Topics: Alkaloids; Animals; Azocines; Benzazepines; Cocaine; Conditioning, Operant; Discrimination Learning; Dopamine Uptake Inhibitors; Drug Interactions; Female; Hypnotics and Sedatives; Macaca mulatta; Male; Mecamylamine; Midazolam; Nicotine; Nicotinic Agonists; Quinolizines; Quinoxalines; Receptors, Nicotinic; Varenicline | 2012 |
An internet survey of use, opinions and preferences for smoking cessation medications: nicotine, varenicline, and bupropion.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Benzazepines; Bupropion; Data Collection; Educational Status; Female; Humans; Internet; Male; Middle Aged; Nicotine; Patient Compliance; Patient Satisfaction; Quinoxalines; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline; Young Adult | 2013 |
Varenicline is a potent partial agonist at α6β2* nicotinic acetylcholine receptors in rat and monkey striatum.
Topics: Animals; Benzazepines; Corpus Striatum; Dopamine; Male; Nicotine; Protein Binding; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Saimiri; Smoking Cessation; Synaptosomes; Varenicline | 2012 |
Structural characterization of binding mode of smoking cessation drugs to nicotinic acetylcholine receptors through study of ligand complexes with acetylcholine-binding protein.
Topics: Acetylcholine; Alkaloids; alpha7 Nicotinic Acetylcholine Receptor; Animals; Aplysia; Azocines; Benzazepines; Binding Sites; Binding, Competitive; Carrier Proteins; Cell Line; HEK293 Cells; Humans; Kinetics; Ligands; Models, Molecular; Mutation; Nicotine; Nicotinic Agonists; Protein Binding; Protein Structure, Secondary; Protein Structure, Tertiary; Quinolizines; Quinoxalines; Receptors, Nicotinic; Smoking Cessation; Varenicline | 2012 |
Use of an α3β4 nicotinic acetylcholine receptor subunit concatamer to characterize ganglionic receptor subtypes with specific subunit composition reveals species-specific pharmacologic properties.
Topics: Acetylcholine; Alkaloids; Animals; Azocines; Benzazepines; Drug Partial Agonism; Evoked Potentials; Ganglia; Humans; Ligands; Mutagenesis, Site-Directed; Mutant Proteins; Nerve Tissue Proteins; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Oocytes; Protein Subunits; Quinolizines; Quinoxalines; Rats; Receptors, Nicotinic; Recombinant Fusion Proteins; Species Specificity; Varenicline; Xenopus laevis | 2012 |
Impact of human D398N single nucleotide polymorphism on intracellular calcium response mediated by α3β4α5 nicotinic acetylcholine receptors.
Topics: Acetylcholine; Aequorin; Algorithms; Benzazepines; Calcium; Data Interpretation, Statistical; Enzyme-Linked Immunosorbent Assay; HEK293 Cells; Humans; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Permeability; Polymorphism, Single Nucleotide; Quinoxalines; Receptors, Nicotinic; Varenicline | 2012 |
Chronic sazetidine-A at behaviorally active doses does not increase nicotinic cholinergic receptors in rodent brain.
Topics: Animals; Azetidines; Behavior, Animal; Benzazepines; Binding Sites; Brain Chemistry; Cerebral Cortex; Dose-Response Relationship, Drug; Female; Male; Membranes; Neurons; Nicotine; Nicotinic Agonists; Pregnancy; Pyridines; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Self Administration; Up-Regulation; Varenicline | 2012 |
Effects of nicotinic acetylcholine receptor agonists on cognition in rhesus monkeys with a chronic cocaine self-administration history.
Topics: Animals; Behavior, Animal; Benzamides; Benzazepines; Bridged Bicyclo Compounds; Cocaine; Cocaine-Related Disorders; Cognition Disorders; Dopamine Uptake Inhibitors; Hippocampus; Learning; Ligands; Macaca mulatta; Male; Memory, Short-Term; Nerve Tissue Proteins; Neurons; Nicotine; Nicotinic Agonists; Nootropic Agents; Quinoxalines; Receptors, Nicotinic; Reversal Learning; Self Administration; Varenicline | 2013 |
The effect of smoking cessation pharmacotherapies on pancreatic beta cell function.
Topics: Animals; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Electron Transport; Gene Expression; Glucose; Insulin; Insulin Secretion; Insulin-Secreting Cells; Mitochondria; Nicotine; Nicotinic Agonists; Oxidative Stress; Pancreatic Function Tests; Quinoxalines; Rats; Signal Transduction; Smoking; Smoking Cessation; Varenicline | 2012 |
Varenicline and bupropion: suicide.
Topics: Benzazepines; Bupropion; Humans; Nicotine; Nicotinic Agonists; Patient Safety; Prescription Drug Misuse; Quinoxalines; Risk Assessment; Risk Factors; Smoking Cessation; Suicide; Varenicline | 2012 |
Involvement of cholinergic receptors in the different stages of memory measured in the modified elevated plus maze test in mice.
Topics: Animals; Benzazepines; Male; Maze Learning; Mecamylamine; Memory; Mice; Motor Activity; Nicotine; Quinoxalines; Receptors, Cholinergic; Scopolamine; Varenicline | 2012 |
Nicotine-motivated behavior in Caenorhabditis elegans requires the nicotinic acetylcholine receptor subunits acr-5 and acr-15.
Topics: Age Factors; Animals; Behavior, Animal; Benzazepines; Butanones; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Chemotaxis; Chlorides; Fasting; Mecamylamine; Muscles; Mutation; Neurons; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Protein Subunits; Quinoxalines; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Nicotinic; Reward; Sodium; Taste; Time Factors; Varenicline | 2013 |
Varenicline and nicotine enhance GABAergic synaptic transmission in rat CA1 hippocampal and medial septum/diagonal band neurons.
Topics: Animals; Benzazepines; CA1 Region, Hippocampal; Female; GABAergic Neurons; Inhibitory Postsynaptic Potentials; Male; Neural Inhibition; Neurons; Nicotine; Nicotinic Agonists; Patch-Clamp Techniques; Quinoxalines; Rats; Rats, Sprague-Dawley; Septal Nuclei; Synaptic Transmission; Varenicline | 2013 |
Multiple nicotine training doses in mice as a basis for differentiating the effects of smoking cessation aids.
Topics: Alkaloids; Animals; Azocines; Benzazepines; Dihydro-beta-Erythroidine; Discrimination Learning; Dose-Response Relationship, Drug; Male; Mecamylamine; Mice; Mice, Inbred C57BL; Midazolam; Morphine; Nicotine; Nicotinic Agonists; Quinolizines; Quinoxalines; Receptors, Nicotinic; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline | 2013 |
Divergent functional effects of sazetidine-a and varenicline during nicotine withdrawal.
Topics: Animals; Anxiety; Azetidines; Benzazepines; Cerebral Cortex; Dose-Response Relationship, Drug; Drug Partial Agonism; Evoked Potentials; Hippocampus; Male; Mice; Microinjections; Motor Activity; Nicotine; Nicotinic Agonists; Pyridines; Quinoxalines; Receptors, Nicotinic; Smoking Cessation; Substance Withdrawal Syndrome; Up-Regulation; Varenicline | 2013 |
Neuronal nicotinic receptor agonists improve gait and balance in olivocerebellar ataxia.
Topics: Animals; Ataxia; Benzazepines; Cerebellum; Dose-Response Relationship, Drug; Gait; Male; Mecamylamine; Motor Activity; Nerve Degeneration; Neural Pathways; Niacinamide; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Olivary Nucleus; Postural Balance; Pyridines; Quinoxalines; Rats; Rotarod Performance Test; Varenicline | 2013 |
PET imaging of high-affinity α4β2 nicotinic acetylcholine receptors in humans with 18F-AZAN, a radioligand with optimal brain kinetics.
Topics: 2,2'-Dipyridyl; Adult; Animals; Azabicyclo Compounds; Benzazepines; Binding, Competitive; Brain; Female; Humans; Kinetics; Ligands; Male; Middle Aged; Nicotine; Nicotinic Agonists; Papio; Positron-Emission Tomography; Quinoxalines; Radiometry; Receptors, Nicotinic; Reproducibility of Results; Varenicline | 2013 |
Effectiveness of varenicline versus nicotine replacement therapy for smoking cessation with minimal professional support: evidence from an English population study.
Topics: Adult; Aged; Benzazepines; Cross-Sectional Studies; Data Collection; Data Interpretation, Statistical; England; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Population; Prescription Drugs; Quinoxalines; Smoking; Smoking Cessation; Treatment Outcome; Varenicline | 2014 |
Varenicline and cytisine diminish the dysphoric-like state associated with spontaneous nicotine withdrawal in rats.
Topics: Alkaloids; Animals; Azocines; Benzazepines; Infusion Pumps, Implantable; Male; Nicotine; Nicotinic Agonists; Quinolizines; Quinoxalines; Rats; Rats, Wistar; Substance Withdrawal Syndrome; Varenicline | 2014 |
Effect of allopurinol on smoking.
Topics: Acetylcholine; Allopurinol; Benzazepines; Brain Chemistry; Bupropion; Causality; Comorbidity; Diabetic Nephropathies; Humans; Hypoxanthine; Molecular Structure; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Structure-Activity Relationship; Varenicline; Xanthine Oxidase | 2013 |
The effect of varenicline on the development and expression of nicotine-induced behavioral sensitization and cross-sensitization in rats.
Topics: Animals; Benzazepines; Motor Activity; Nicotine; Nicotinic Agonists; Quinoxalines; Rats; Smoking Cessation; Varenicline | 2015 |
Effects of chronic varenicline treatment on nicotine, cocaine, and concurrent nicotine+cocaine self-administration.
Topics: Animals; Benzazepines; Cocaine; Cocaine-Related Disorders; Conditioning, Operant; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug-Seeking Behavior; Feeding Behavior; Female; Macaca mulatta; Male; Motivation; Nicotine; Nicotinic Agonists; Quinoxalines; Reinforcement, Psychology; Self Administration; Tobacco Use Disorder; Varenicline | 2014 |
Functional interactions of varenicline and nicotine with nAChR subtypes implicated in cardiovascular control.
Topics: Animals; Benzazepines; Humans; Nicotine; Nicotinic Agonists; Oocytes; Protein Binding; Quinoxalines; Receptors, Nicotinic; Tobacco Use Disorder; Varenicline; Xenopus laevis | 2014 |
Chronic sazetidine-A maintains anxiolytic effects and slower weight gain following chronic nicotine without maintaining increased density of nicotinic receptors in rodent brain.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Azetidines; Benzazepines; Brain Chemistry; Drug Evaluation, Preclinical; Feeding Behavior; Gene Expression Regulation; Male; Mice; Mice, Inbred C57BL; Nicotine; Nicotinic Agonists; Pyridines; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Substance Withdrawal Syndrome; Tobacco Use Cessation; Tobacco Use Disorder; Up-Regulation; Varenicline; Weight Gain | 2014 |
[Safety of nicotine addiction treatment].
Topics: Abdominal Pain; Adult; Alkaloids; Azocines; Benzazepines; Boredom; Bupropion; Female; Headache; Humans; Male; Middle Aged; Nicotine; Patient Compliance; Quinolizines; Quinoxalines; Sleep Wake Disorders; Smoking Cessation; Tobacco Use Disorder; Varenicline; Xerostomia | 2013 |
Varenicline disrupts prepulse inhibition only in high-inhibitory rats.
Topics: Acoustic Stimulation; Acoustics; Analysis of Variance; Animals; Apomorphine; Benzazepines; Dizocilpine Maleate; Dopamine Agonists; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Male; Nicotine; Nicotinic Agonists; Prepulse Inhibition; Quinoxalines; Rats; Rats, Sprague-Dawley; Reflex, Startle; Varenicline | 2014 |
Larval zebrafish model for FDA-approved drug repositioning for tobacco dependence treatment.
Topics: Animals; Benzazepines; Drug Repositioning; Models, Animal; Nicotine; Quinoxalines; Tobacco Use Disorder; United States; United States Food and Drug Administration; Varenicline; Zebrafish | 2014 |
The cytisine derivatives, CC4 and CC26, reduce nicotine-induced conditioned place preference in zebrafish by acting on heteromeric neuronal nicotinic acetylcholine receptors.
Topics: Alkaloids; Animals; Benzazepines; Conditioning, Operant; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Quinoxalines; Receptors, Nicotinic; Varenicline; Zebrafish | 2014 |
Efficient expression of functional (α6β2)2β3 AChRs in Xenopus oocytes from free subunits using slightly modified α6 subunits.
Topics: Acetylcholine; Alkaloids; Animals; Atropine; Azocines; Cholinergic Agonists; Female; Gene Expression; Humans; Membrane Potentials; Nicotine; Nicotinic Agonists; Oocytes; Patch-Clamp Techniques; Quinolizines; Receptors, Nicotinic; Recombinant Fusion Proteins; Varenicline; Xenopus laevis | 2014 |
Differentiating the primary reinforcing and reinforcement-enhancing effects of varenicline.
Topics: Animals; Benzazepines; Conditioning, Operant; Cues; Dose-Response Relationship, Drug; Male; Nicotine; Nicotinic Agonists; Quinoxalines; Rats; Rats, Sprague-Dawley; Reinforcement Schedule; Reinforcement, Psychology; Self Administration; Smoking Cessation; Varenicline | 2015 |
Examination of the effects of varenicline, bupropion, lorcaserin, or naltrexone on responding for conditioned reinforcement in nicotine-exposed rats.
Topics: Animals; Benzazepines; Bupropion; Cholinergic Agents; Conditioning, Operant; Dose-Response Relationship, Drug; Drug Interactions; Male; Naltrexone; Narcotic Antagonists; Nicotine; Quinoxalines; Rats; Rats, Long-Evans; Reinforcement, Psychology; Varenicline | 2014 |
Concurrent access to nicotine and sucrose in rats.
Topics: Animals; Behavior, Addictive; Benzazepines; Conditioning, Operant; Male; Nicotine; Quinoxalines; Rats; Rats, Sprague-Dawley; Reinforcement, Psychology; Self Administration; Sucrose; Varenicline | 2015 |
Prospective cohort study of the effectiveness of varenicline versus nicotine replacement therapy for smoking cessation in the "real world".
Topics: Adolescent; Adult; Benzazepines; Cohort Studies; Cross-Sectional Studies; Female; Humans; Longitudinal Studies; Male; Middle Aged; Netherlands; Nicotine; Nicotinic Agonists; Patient Compliance; Prospective Studies; Quinoxalines; Smoking Cessation; Surveys and Questionnaires; Treatment Outcome; Varenicline | 2014 |
AT-1001: a high-affinity α3β4 nAChR ligand with novel nicotine-suppressive pharmacology.
Topics: Animals; Cell Line; Drug-Seeking Behavior; Ethanol; Humans; Ligands; Male; Motor Activity; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Oligopeptides; Rats, Sprague-Dawley; Receptors, Nicotinic; Varenicline | 2015 |
Importance of national context in the translation of personalised treatments for smoking cessation.
Topics: Female; Humans; Male; Nicotine; Nicotinic Agonists; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline | 2015 |
Bupropion-varenicline interactions and nicotine self-administration behavior in rats.
Topics: Animals; Bupropion; Dose-Response Relationship, Drug; Drug Synergism; Female; Nicotine; Rats; Self Administration; Varenicline | 2015 |
Effects of the Nanoparticle-Based Vaccine, SEL-068, on Nicotine Discrimination in Squirrel Monkeys.
Topics: Analysis of Variance; Animals; Berberine; Discrimination Learning; Discrimination, Psychological; Dose-Response Relationship, Drug; Immunization; Immunologic Factors; Male; Nanoparticles; Nicotine; Nicotinic Agonists; Saimiri; Time Factors; Vaccines; Varenicline | 2015 |
Reward Anticipation Is Differentially Modulated by Varenicline and Nicotine in Smokers.
Topics: Adolescent; Adult; Brain; Case-Control Studies; Cross-Over Studies; Double-Blind Method; Female; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Motivation; Nicotine; Nicotinic Agonists; Oxygen; Reaction Time; Reward; Smoking; Varenicline; Young Adult | 2015 |
Gender differences in medication use and cigarette smoking cessation: results from the International Tobacco Control Four Country Survey.
Topics: Adolescent; Adult; Australia; Benzazepines; Canada; Female; Gender Identity; Humans; Longitudinal Studies; Male; Middle Aged; Motivation; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Smoking Prevention; Substance Withdrawal Syndrome; United Kingdom; United States; Varenicline | 2015 |
Noribogaine reduces nicotine self-administration in rats.
Topics: Animals; Dose-Response Relationship, Drug; Ibogaine; Male; Nicotine; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Self Administration; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2015 |
Chronic treatment with varenicline changes expression of four nAChR binding sites in mice.
Topics: Animals; Autoradiography; Binding Sites; Brain; Dose-Response Relationship, Drug; Gene Expression; Mice, Inbred C57BL; Nicotine; Nicotinic Agonists; Receptors, Nicotinic; Tobacco Use Cessation Devices; Varenicline | 2015 |
The effect of switching pharmacological intervention during extinction on nicotine-evoked conditioned responding in rats.
Topics: Animals; Conditioning, Psychological; Discrimination Learning; Dose-Response Relationship, Drug; Drug Substitution; Extinction, Psychological; Male; Nicotine; Nicotinic Agonists; Rats; Rats, Sprague-Dawley; Smoking Cessation; Varenicline | 2015 |
Effects of varenicline on operant self-administration of alcohol and/or nicotine in a rat model of co-abuse.
Topics: Animals; Behavior, Addictive; Behavior, Animal; Conditioning, Operant; Disease Models, Animal; Drug Interactions; Ethanol; Male; Nicotine; Nicotinic Agonists; Rats; Rats, Wistar; Substance-Related Disorders; Varenicline | 2016 |
Varenicline decreases nicotine but not alcohol self-administration in genetically selected Marchigian Sardinian alcohol-preferring (msP) rats.
Topics: Alcohol Drinking; Animals; Behavior, Animal; Central Nervous System Depressants; Choice Behavior; Conditioning, Operant; Dose-Response Relationship, Drug; Ethanol; Male; Nicotine; Nicotinic Agonists; Rats; Self Administration; Varenicline | 2015 |
Extended nicotine self-administration increases sensitivity to nicotine, motivation to seek nicotine and the reinforcing properties of nicotine-paired cues.
Topics: Animals; Behavior, Animal; Cues; Drug-Seeking Behavior; Male; Motivation; Nicotine; Nicotinic Agonists; Rats; Rats, Sprague-Dawley; Reinforcement, Psychology; Self Administration; Tobacco Use Disorder; Varenicline | 2017 |
Nicotine Enhances the Hypnotic and Hypothermic Effects of Alcohol in the Mouse.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Azetidines; Body Temperature; Central Nervous System Depressants; Drug Interactions; Ethanol; Hypnotics and Sedatives; Hypothermia; Ketamine; Mecamylamine; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Knockout; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Pentobarbital; Pyridines; Receptors, Nicotinic; Reflex, Righting; Varenicline | 2016 |
Influence of smoking cessation drugs on blood pressure and heart rate in patients with cardiovascular disease or high risk score: real life setting.
Topics: Adult; Aged; Blood Pressure; Brazil; Bupropion; Cardiovascular Diseases; Comorbidity; Coronary Artery Disease; Diabetes Mellitus; Diastole; Dopamine Uptake Inhibitors; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Nicotine; Nicotinic Agonists; Risk Factors; Smoking; Smoking Cessation; Systole; Tobacco Use Cessation Devices; Varenicline | 2016 |
[Varenicline in nicotine replacement therapy: Does it really increase the risk of cardiovascular and neuropsychiatric events?].
Topics: Bupropion; Humans; Nicotine; Nicotinic Agonists; Smoking; Varenicline | 2016 |
Similar quit rates are found with three smoking cessation options.
Topics: Female; Humans; Male; Nicotine; Nicotinic Agonists; Smoking; Tobacco Use Cessation Devices; Varenicline | 2016 |
Methamphetamine-like discriminative stimulus effects of bupropion and its two hydroxy metabolites in male rhesus monkeys.
Topics: Animals; Antidepressive Agents, Second-Generation; Bupropion; Central Nervous System Stimulants; Conditioning, Operant; Discrimination Learning; Dopamine Antagonists; Dose-Response Relationship, Drug; Macaca mulatta; Male; Methamphetamine; Nicotine; Nicotinic Agonists; Reinforcement, Psychology; Risperidone; Time Factors; Varenicline | 2016 |
Varenicline impairs extinction and enhances reinstatement across repeated cycles of nicotine self-administration in rats.
Topics: Animals; Catheters, Indwelling; Disease Models, Animal; Drug-Seeking Behavior; Extinction, Psychological; Male; Motor Activity; Nicotine; Nicotinic Agonists; Rats, Sprague-Dawley; Self Administration; Tobacco Use Cessation Devices; Tobacco Use Disorder; Varenicline | 2016 |
Commentary on Roberts et al. (2016): Bupropion and varenicline are efficacious and well-tolerated cessation medications for smokers with serious mental illness.
Topics: Benzazepines; Bupropion; Humans; Nicotine; Nicotinic Agonists; Smoking; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2016 |
Sex differences in attenuation of nicotine reinstatement after individual and combined treatments of progesterone and varenicline.
Topics: Animals; Disease Models, Animal; Drug Combinations; Drug-Seeking Behavior; Extinction, Psychological; Female; Male; Nicotine; Nicotinic Agonists; Progesterone; Progestins; Rats; Rats, Wistar; Reinforcement Schedule; Self Administration; Sex Factors; Smoking Cessation; Varenicline | 2016 |
Effects of aging on the effectiveness of smoking cessation medication.
Topics: Adult; Age Factors; Aged; Brazil; Bupropion; Drug Therapy, Combination; Female; Half-Life; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Precision Medicine; Smoking Cessation; Treatment Outcome; Varenicline | 2016 |
[Not Available].
Topics: Female; Humans; Male; Nicotine; Nicotinic Agonists; Smoking; Tobacco Use Cessation Devices; Varenicline | 2016 |
The use of varenicline to treat nicotine dependence among patients with cancer.
Topics: Adult; Benzazepines; Bupropion; Counseling; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasms; Nicotine; Nicotinic Agonists; Smoking; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2017 |
Factors influencing sustainable efficacy of smoking cessation treatment with varenicline beyond nine months.
Topics: Adult; Aged; Aged, 80 and over; Bupropion; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Smoking; Smoking Cessation; Varenicline | 2016 |
The nicotine + alcohol interoceptive drug state: contribution of the components and effects of varenicline in rats.
Topics: Animals; Central Nervous System Depressants; Conditioning, Classical; Cues; Dose-Response Relationship, Drug; Ethanol; Male; Nicotine; Nicotinic Agonists; Rats; Rats, Long-Evans; Receptors, Nicotinic; Smoking Cessation; Varenicline | 2016 |
Varenicline, the clinically effective smoking cessation agent, restores probabilistic response reversal performance during withdrawal from nicotine.
Topics: Animals; Male; Nicotine; Nicotinic Agonists; Probability Learning; Psychomotor Performance; Rats; Reaction Time; Substance Withdrawal Syndrome; Tobacco Use Disorder; Varenicline | 2017 |
Attenuated nicotine-like effects of varenicline but not other nicotinic ACh receptor agonists in monkeys receiving nicotine daily.
Topics: Animals; Bridged Bicyclo Compounds, Heterocyclic; Dose-Response Relationship, Drug; Female; Macaca mulatta; Male; Nicotine; Nicotinic Agonists; Pyridines; Receptors, Nicotinic; Structure-Activity Relationship; Varenicline | 2016 |
Therapeutic concentrations of varenicline in the presence of nicotine increase action potential firing in human adrenal chromaffin cells.
Topics: Action Potentials; Adrenal Cortex; Adult; Aged; Animals; Chromaffin Cells; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Varenicline; Xenopus laevis | 2017 |
The contribution of α4β2 and non-α4β2 nicotinic acetylcholine receptors to the discriminative stimulus effects of nicotine and varenicline in mice.
Topics: Aconitine; Alkaloids; alpha7 Nicotinic Acetylcholine Receptor; Animals; Azocines; Benzamides; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cocaine; Dihydro-beta-Erythroidine; Discrimination, Psychological; Dopamine Uptake Inhibitors; Hypnotics and Sedatives; Ibogaine; Male; Mecamylamine; Mice; Mice, Inbred C57BL; Midazolam; Nerve Tissue Proteins; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Pyridines; Quinolizines; Receptors, Nicotinic; Varenicline | 2017 |
Varenicline provokes impulsive action by stimulating α4β2 nicotinic acetylcholine receptors in the infralimbic cortex in a nicotine exposure status-dependent manner.
Topics: Administration, Oral; Animals; Appetite; Dihydro-beta-Erythroidine; Dose-Response Relationship, Drug; Drug Interactions; Hypodermoclysis; Impulsive Behavior; Limbic Lobe; Male; Microinjections; Nicotine; Nicotinic Agonists; Rats; Receptors, Nicotinic; Varenicline | 2017 |
The effect of varenicline and nicotine patch on smoking rate and satisfaction with smoking: an examination of the mechanism of action of two pre-quit pharmacotherapies.
Topics: Humans; Nicotine; Nicotinic Agonists; Personal Satisfaction; Research Design; Smartphone; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Smoking; Tobacco Use Cessation Devices; Varenicline | 2017 |
Compromised neuroplasticity in cigarette smokers under nicotine withdrawal is restituted by the nicotinic α
Topics: Adult; Cigarette Smoking; Electric Stimulation; Evoked Potentials, Motor; Female; Humans; Male; Motor Cortex; Neuronal Plasticity; Nicotine; Nicotinic Agonists; Receptors, Nicotinic; Substance Withdrawal Syndrome; Transcranial Direct Current Stimulation; Varenicline; Young Adult | 2017 |
Using PICO Methodology to Answer Questions About Smoking in COPD Patients.
Topics: Biomarkers; Bupropion; Clinical Trials as Topic; Cost-Benefit Analysis; Counseling; Evidence-Based Medicine; Humans; Motivation; Nicotine; Nicotinic Agonists; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Smoking; Smoking Cessation; Spirometry; Surveys and Questionnaires; Varenicline | 2017 |
Selective and regulated trapping of nicotinic receptor weak base ligands and relevance to smoking cessation.
Topics: HEK293 Cells; Humans; Hydrogen-Ion Concentration; Ligands; Nicotine; Nicotinic Agonists; Receptors, Nicotinic; Smoking Cessation; Up-Regulation; Varenicline | 2017 |
Measures and predictors of varenicline adherence in the treatment of nicotine dependence.
Topics: Adult; Affect; Craving; Female; Humans; Logistic Models; Male; Medication Adherence; Middle Aged; Nicotine; Nicotinic Agonists; Randomized Controlled Trials as Topic; Saliva; Self Report; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder; Varenicline | 2017 |
The effectiveness of varenicline versus nicotine replacement therapy on long-term smoking cessation in primary care: a prospective cohort study of electronic medical records.
Topics: Adult; Electronic Health Records; England; Female; Follow-Up Studies; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Nicotine; Primary Health Care; Propensity Score; Prospective Studies; Smoking Cessation; Social Class; Time Factors; Tobacco Use Cessation Devices; Treatment Outcome; Varenicline | 2017 |
Association of nicotine metabolism and sex with relapse following varenicline and nicotine replacement therapy.
Topics: Adult; Cotinine; Cytochrome P-450 CYP2A6; Female; Genotype; Humans; Longitudinal Studies; Male; Middle Aged; Nicotine; Recurrence; Smoking; Smoking Cessation; Tobacco Products; Varenicline | 2017 |
Reversal of Nicotine Withdrawal Signs Through Positive Allosteric Modulation of α4β2 Nicotinic Acetylcholine Receptors in Male Mice.
Topics: Allosteric Regulation; Animals; Hydrocarbons, Brominated; Indole Alkaloids; Infusion Pumps, Implantable; Male; Mice; Mice, Inbred ICR; Nicotine; Nicotinic Agonists; Receptors, Nicotinic; Smoking Cessation; Substance Withdrawal Syndrome; Varenicline | 2018 |
Nicotine as a discriminative stimulus for ethanol use.
Topics: Alcohol Drinking; Animals; Conditioning, Operant; Discrimination Learning; Dose-Response Relationship, Drug; Ethanol; Male; Nicotine; Rats; Rats, Inbred Lew; Reaction Time; Reinforcement, Psychology; Varenicline | 2018 |
Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats.
Topics: Alcohol Drinking; Animals; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Ethanol; Female; Modafinil; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Rats; Receptors, Nicotinic; Self Administration; Smoking Cessation; Varenicline | 2018 |
A behavioral economic analysis of the value-enhancing effects of nicotine and varenicline and the role of nicotinic acetylcholine receptors in male and female rats.
Topics: Animals; Conditioning, Operant; Cues; Dihydro-beta-Erythroidine; Dose-Response Relationship, Drug; Economics, Behavioral; Female; Locomotion; Male; Nicotine; Nicotinic Agonists; Photic Stimulation; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Reinforcement, Psychology; Sex Characteristics; Varenicline | 2018 |
[Clinical Practice Guidelines for Smoking Cessation].
Topics: Bupropion; Chile; Evidence-Based Medicine; Humans; Nicotine; Smoking Cessation; Varenicline | 2017 |
New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice.
Topics: Animals; Dose-Response Relationship, Drug; Female; Hyperalgesia; Male; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Transgenic; Nicotine; Nicotinic Agonists; Receptors, Nicotinic; Reward; Smoking Cessation Agents; Substance Withdrawal Syndrome; Tobacco Use Disorder; Varenicline | 2018 |
Rats choose high doses of nicotine in order to compensate for changes in its price and availability.
Topics: Animals; Behavior, Animal; Choice Behavior; Infusions, Intravenous; Nicotine; Nicotinic Agonists; Public Policy; Rats; Self Administration; Smoke-Free Policy; Smoking Cessation Agents; Tobacco Products; Varenicline | 2019 |
Nicotine and varenicline ameliorate changes in reward-based choice strategy and altered decision-making in methamphetamine-treated rats.
Topics: Animals; Central Nervous System Stimulants; Conditioning, Operant; Decision Making; Dose-Response Relationship, Drug; Male; Methamphetamine; Nicotine; Nicotinic Agonists; Rats; Rats, Wistar; Reward; Risk-Taking; Time Factors; Varenicline | 2019 |
Varenicline increases random flap survival in rats submitted to nicotine.
Topics: Angiography; Animals; Graft Survival; Microcirculation; Microscopy; Models, Animal; Nicotine; Nicotinic Agonists; Rats, Wistar; Smoking Cessation Agents; Surgical Flaps; Varenicline | 2018 |
Rapid nicotine tolerance and cross-tolerance to varenicline in rhesus monkeys: Drug discrimination.
Topics: Animals; Discrimination Learning; Dose-Response Relationship, Drug; Drug Tolerance; Female; Macaca mulatta; Male; Nicotine; Nicotinic Agonists; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2018 |
Varenicline and nabilone in tobacco and cannabis co-users: effects on tobacco abstinence, withdrawal and a laboratory model of cannabis relapse.
Topics: Adult; Cigarette Smoking; Comorbidity; Dronabinol; Female; Humans; Male; Marijuana Abuse; Nicotine; Nicotinic Agonists; Smoking Cessation; Smoking Cessation Agents; Substance Withdrawal Syndrome; Varenicline; Young Adult | 2019 |
An improved model of ethanol and nicotine co-use in female P rats: Effects of naltrexone, varenicline, and the selective nicotinic α6β2* antagonist r-bPiDI.
Topics: Alcohol Deterrents; Alcohol Drinking; Animals; Disease Models, Animal; Ethanol; Female; Naltrexone; Nicotine; Nicotinic Antagonists; Picolines; Pyridinium Compounds; Rats; Self Administration; Smoking Cessation Agents; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2018 |
Differential cross-tolerance to the effects of nicotinic acetylcholine receptor drugs in C57BL/6J mice following chronic varenicline.
Topics: Alkaloids; Animals; Azocines; Bridged Bicyclo Compounds, Heterocyclic; Cocaine; Conditioning, Operant; Drug Tolerance; Female; Male; Mice; Mice, Inbred C57BL; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Pyridines; Quinolizines; Receptors, Nicotinic; Reinforcement, Psychology; Smoking Cessation; Varenicline | 2019 |
Revisiting autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) mutations in the nicotinic acetylcholine receptor reveal an increase in efficacy regardless of stochiometry.
Topics: Acetylcholine; Alkaloids; Animals; Azocines; Epilepsy, Frontal Lobe; Female; Mutation; Nicotine; Nicotinic Agonists; Oocytes; Quinolizines; Receptors, Nicotinic; Varenicline; Xenopus laevis | 2019 |
Individual differences in responding to bupropion or varenicline in a preclinical model of nicotine self-administration vary according to individual demand for nicotine.
Topics: Animals; Bupropion; Dose-Response Relationship, Drug; Extinction, Psychological; Individuality; Male; Nicotine; Rats; Reinforcement Schedule; Self Administration; Sucrose; Varenicline | 2019 |
Increasing Smoking Cessation in the United States: Expanding the Availability of Over-the-Counter Medications.
Topics: Behavior Therapy; Bupropion; Humans; Nicotine; Nonprescription Drugs; Smoking Cessation; Smoking Cessation Agents; Tobacco Use Cessation Devices; United States; Varenicline | 2019 |
Determining the pharmacokinetics of nicotinic drugs in the endoplasmic reticulum using biosensors.
Topics: Animals; Biosensing Techniques; Cell Line; Cell Line, Tumor; Cell Membrane; Endoplasmic Reticulum; Female; HEK293 Cells; HeLa Cells; Hippocampus; Humans; Mammals; Mice; Neurons; Nicotine; Pregnancy; Protein Transport; Receptors, Nicotinic; Smoking; Varenicline | 2019 |
Therapeutic challenges for concurrent ethanol and nicotine consumption: naltrexone and varenicline fail to alter simultaneous ethanol and nicotine intake by female alcohol-preferring (P) rats.
Topics: Alcohol Deterrents; Alcohol Drinking; Animals; Ethanol; Female; Injections, Subcutaneous; Naltrexone; Nicotine; Random Allocation; Rats; Self Administration; Smoking Cessation Agents; Tobacco Use Disorder; Varenicline | 2019 |
Prolonged exposure of rats to varenicline increases anxiety and alters serotonergic system, but has no effect on memory.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Analysis of Variance; Animals; Anxiety; Behavior, Animal; Cognition; gamma-Aminobutyric Acid; Hippocampus; Male; Memory; Models, Animal; Motor Activity; Nicotine; Nicotinic Agonists; Rats; Rats, Wistar; Serotonergic Neurons; Serotonin; Smoking; Smoking Cessation; Varenicline | 2019 |
Exploring the interoceptive stimulus effects of nicotine and varenicline.
Topics: Animals; Appetitive Behavior; Conditioning, Classical; Discrimination Learning; Discrimination, Psychological; Drug Substitution; Extinction, Psychological; Injections, Subcutaneous; Interoception; Male; Nicotine; Nicotinic Agonists; Rats; Rats, Sprague-Dawley; Saline Solution; Smoking Cessation; Substance Withdrawal Syndrome; Sucrose; Varenicline | 2019 |
Assessing nicotine dependence using an oral nicotine free-choice paradigm in mice.
Topics: Animals; Behavior, Addictive; Choice Behavior; Dose-Response Relationship, Drug; Drug Interactions; Female; Male; Mice; Mice, Knockout; Nicotine; Nucleus Accumbens; Quinine; Receptors, Nicotinic; Self Administration; Sex Characteristics; Substance Withdrawal Syndrome; Tobacco Use Disorder; Tyrosine 3-Monooxygenase; Varenicline | 2019 |
Nicotine Self-Administration as Paradigm for Medication Discovery for Smoking Cessation: Recent Findings in Medications Targeting the Cholinergic System.
Topics: Animals; Behavior, Addictive; Cholinergic Agents; Gene Knockout Techniques; Humans; Models, Animal; Nicotine; Nicotinic Antagonists; Receptors, Nicotinic; Self Administration; Smoking Cessation; Varenicline | 2019 |
Prescribing Prevalence, Effectiveness, and Mental Health Safety of Smoking Cessation Medicines in Patients With Mental Disorders.
Topics: Drug Prescriptions; Female; Humans; Male; Mental Disorders; Mental Health; Middle Aged; Nicotine; Nicotinic Agonists; Prospective Studies; Smoking Cessation; Tobacco Use Cessation Devices; Tobacco Use Disorder; Varenicline | 2020 |
Estimation of high-dimensional propensity scores with multiple exposure levels.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Bupropion; Cohort Studies; Female; Humans; Male; Middle Aged; Myocardial Infarction; Nicotine; Pharmacoepidemiology; Propensity Score; Proportional Hazards Models; Retrospective Studies; Smoking Cessation; United Kingdom; Varenicline; Young Adult | 2020 |
Varenicline for cessation from nicotine-containing electronic cigarettes.
Topics: Behavior, Addictive; Humans; Male; Middle Aged; Nicotine; Severity of Illness Index; Smoking Cessation; Treatment Outcome; Vaping; Varenicline | 2019 |
Habenular and striatal activity during performance feedback are differentially linked with state-like and trait-like aspects of tobacco use disorder.
Topics: Adolescent; Adult; Brain; Brain Mapping; Corpus Striatum; Feedback, Physiological; Female; Habenula; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Nicotine; Placebo Effect; Smokers; Task Performance and Analysis; Tobacco Use Disorder; Varenicline; Young Adult | 2019 |
Varenicline aggravates atherosclerotic plaque formation in nicotine-pretreated ApoE knockout mice due to enhanced oxLDL uptake by macrophages through downregulation of ABCA1 and ABCG1 expression.
Topics: Animals; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; Down-Regulation; Gene Expression Regulation; Lipoproteins, LDL; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout, ApoE; Nicotine; Plaque, Atherosclerotic; RAW 264.7 Cells; Smoking Cessation Agents; Varenicline | 2020 |
Development of a novel alcohol and nicotine concurrent access (ANCA) self-administration procedure in baboons.
Topics: Administration, Intravenous; Administration, Oral; Animals; Drug Interactions; Ethanol; Male; Models, Animal; Nicotine; Papio; Self Administration; Varenicline | 2020 |
Long-term effectiveness and safety of varenicline and nicotine replacement therapy in people with neurodevelopmental disorders: A prospective cohort study.
Topics: Cohort Studies; Confidence Intervals; Female; Humans; Male; Neurodevelopmental Disorders; Nicotine; Propensity Score; Prospective Studies; Smoking Cessation; Varenicline | 2019 |
Health-care providers' concern regarding smoking cessation pharmacotherapies during pregnancy: Calls to a teratology information service.
Topics: Australia; Behavior Therapy; Bupropion; Call Centers; Female; Health Personnel; Humans; Information Services; Nicotine; Pregnancy; Smoking; Smoking Cessation; Teratology; Tobacco Use Cessation Devices; Varenicline | 2020 |
Nicotine dependence (trait) and acute nicotinic stimulation (state) modulate attention but not inhibitory control: converging fMRI evidence from Go-Nogo and Flanker tasks.
Topics: Adolescent; Adult; Attention; Brain; Brain Mapping; Cross-Over Studies; Double-Blind Method; Executive Function; Female; Humans; Inhibition, Psychological; Magnetic Resonance Imaging; Male; Middle Aged; Nicotine; Nicotinic Agonists; Smoking Cessation; Tobacco Use Disorder; Varenicline; Young Adult | 2020 |
Assessment of individual differences in response to acute bupropion or varenicline treatment using a long-access nicotine self-administration model and behavioral economics in female rats.
Topics: Adrenergic alpha-2 Receptor Antagonists; Animals; Behavior, Animal; Bupropion; Conditioning, Psychological; Economics, Behavioral; Extinction, Psychological; Female; Individuality; Nicotine; Nicotinic Agonists; Rats; Self Administration; Smoking Cessation Agents; Varenicline; Yohimbine | 2020 |
Precision nicotine metabolism-informed care for smoking cessation in Crohn's disease: A pilot study.
Topics: Adult; Bupropion; Crohn Disease; Female; Humans; Male; Middle Aged; Nicotine; Patient Compliance; Pilot Projects; Prevalence; Randomized Controlled Trials as Topic; Severity of Illness Index; Smoking; Smoking Cessation; Tobacco Use Cessation Devices; Treatment Outcome; Varenicline | 2020 |
Effects of ethanol, naltrexone, nicotine and varenicline in an ethanol and nicotine co-use model in Sprague-Dawley rats.
Topics: Alcohol Deterrents; Alcohol Drinking; Animals; Ethanol; Female; Male; Naltrexone; Nicotine; Rats; Rats, Sprague-Dawley; Self Administration; Smoking Cessation Agents; Tobacco Use Disorder; Varenicline | 2020 |
Varenicline rescues nicotine-induced decrease in motivation for sucrose reinforcement.
Topics: Animals; Behavior, Animal; Drug Interactions; Economics, Behavioral; Feeding Behavior; Male; Motivation; Nicotine; Nicotinic Agonists; Rats; Rats, Sprague-Dawley; Reinforcement Schedule; Reinforcement, Psychology; Smoking Cessation Agents; Sucrose; Varenicline | 2021 |
The importance of acquisition learning on nicotine and varenicline drug substitution in a drug-discriminated goal-tracking task.
Topics: Animals; Discrimination Learning; Drug Substitution; Goals; Male; Nicotine; Nicotinic Agonists; Rats; Rats, Sprague-Dawley; Smoking Cessation Agents; Varenicline | 2020 |
Self-Administration of Cotinine in Wistar Rats: Comparisons to Nicotine.
Topics: Animals; Cotinine; Dose-Response Relationship, Drug; Drug Interactions; Female; Male; Mecamylamine; Nicotine; Rats; Rats, Wistar; Receptors, Nicotinic; Self Administration; Varenicline | 2021 |
5-HT
Topics: Humans; Molecular Targeted Therapy; Nicotine; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Serotonin; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline | 2021 |
Therapeutic concentrations of varenicline increases exocytotic release of catecholamines from human and rat adrenal chromaffin cells in the presence of nicotine.
Topics: Acetylcholine; Adrenal Glands; Animals; Catecholamines; Cattle; Chromaffin Cells; Exocytosis; Humans; Nicotine; Nicotinic Agonists; Rats; Varenicline | 2021 |
The Comparative Effectiveness of Varenicline and Nicotine Patches for Smoking Abstinence During Pregnancy: Evidence From a Population-based Cohort Study.
Topics: Australia; Cohort Studies; Female; Humans; Nicotine; Pregnancy; Smoking; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline | 2021 |
Stability of Varenicline Concentration in Saliva Over 21 Days at Three Storage Temperatures.
Topics: Cotinine; Humans; Nicotine; Saliva; Smoking Cessation; Temperature; Varenicline | 2022 |
Assessing combined effects of varenicline and N-acetylcysteine on reducing nicotine seeking in rats.
Topics: Acetylcysteine; Animals; Nicotine; Rats; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2022 |
Dose-dependent effects of Varenicline on tobacco craving and withdrawal in tobacco smokers with and without schizophrenia.
Topics: Craving; Double-Blind Method; Humans; Nicotiana; Nicotine; Nicotinic Agonists; Schizophrenia; Smokers; Smoking; Substance Withdrawal Syndrome; Varenicline | 2022 |
Characterising the use of varenicline: an analysis of the Australian dispensing claims data.
Topics: Aged; Australia; Benzazepines; Bupropion; Humans; Male; Nicotine; Nicotinic Agonists; Quinoxalines; Retrospective Studies; Smoking; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline | 2022 |
[Tobacco cessation treatment for people with schizophrenia].
Topics: Benzazepines; Bupropion; Humans; Nicotine; Quinoxalines; Schizophrenia; Smoking Cessation; Tobacco Use Cessation; Tobacco Use Cessation Devices; Varenicline | 2022 |
Trapping of Nicotinic Acetylcholine Receptor Ligands Assayed by
Topics: Animals; Brain; Female; Ligands; Male; Mice; Nicotine; Positron-Emission Tomography; Receptors, Nicotinic; Tobacco Use Disorder; Varenicline | 2023 |
Publicly subsidised smoking cessation medicines in times of COVID-19 in Australia: An interrupted time series analysis.
Topics: Bupropion; COVID-19; Humans; Interrupted Time Series Analysis; Nicotine; Nicotinic Agonists; Pandemics; Pharmaceutical Preparations; Smoking; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline | 2023 |
Varenicline serves as the training stimulus in the drug-discriminated goal-tracking task with rats: initial evaluation of potential neuropharmacological processes.
Topics: Animals; Benzazepines; Bupropion; Goals; Motivation; Nicotine; Nicotinic Agonists; Quinoxalines; Rats; Receptors, Nicotinic; Smoking Cessation Agents; Varenicline | 2023 |
Comparative effect of varenicline and nicotine patches on preventing repeat cardiovascular events.
Topics: Aftercare; Cardiovascular Diseases; Cohort Studies; Female; Humans; Male; Nicotine; Nicotinic Agonists; Patient Discharge; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline | 2023 |
Role of neuronal nicotinic acetylcholine receptors in cannabinoid dependence.
Topics: Cannabinoid Receptor Agonists; Cannabinoids; Humans; Nicotine; Nicotinic Agonists; Receptors, Nicotinic; Varenicline | 2023 |
Varenicline mitigates the increased risk of pseudarthrosis associated with nicotine.
Topics: Animals; Male; Nicotine; Pseudarthrosis; Rats; Rats, Sprague-Dawley; Smoking Cessation; Varenicline | 2023 |
Nicotine and Cytisine Embryotoxicity in the Experimental Zebrafish Model.
Topics: Alkaloids; Animals; Azocines; Benzazepines; Humans; Nicotine; Nicotinic Agonists; Quinolizines; Quinoxalines; Receptors, Nicotinic; Varenicline; Zebrafish | 2023 |